Treatment for obesity

Novel compounds and pharmaceutical compositions address the limitations of current obesity treatments by reducing weight and improving metabolic health, offering a safer and more effective non-surgical solution for obesity and related conditions.

JP2024169518APending Publication Date: 2024-12-051GLOBE BIOMEDICAL CO LTD +1
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
JP2024160121
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2018-09-18
Filing Date
2024-09-17
Publication Date
2024-12-05

AI Technical Summary

Technical Problem

Current treatments for obesity and related conditions, such as bariatric surgery, are invasive and carry significant risks, and there is a need for effective non-surgical methods to achieve sustained weight loss and improve associated health outcomes.

Method used

The development of novel compounds, including specific formulations and pharmaceutical compositions, administered in combination with excipients and carriers, to treat or prevent obesity and related conditions like type II diabetes and metabolic syndrome, by targeting metabolic pathways and reducing body weight and improving insulin sensitivity.

Benefits of technology

The compounds effectively reduce body weight, improve insulin sensitivity, and ameliorate symptoms of obesity and related disorders, providing a safer and more effective alternative to surgical interventions.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024169518000073
    Figure 2024169518000073
  • Figure 2024169518000074
    Figure 2024169518000074
  • Figure 2024169518000075
    Figure 2024169518000075
Patent Text Reader

Abstract

To provide treatment for obesity.SOLUTION: The invention provides novel methods of treating or preventing obesity or overweight and closely associated comorbidities therewith in a mammalian subject including human. The invention provides methods for treating or preventing type II diabetes mellitus in a mammal including a human, comprising administering, to a mammalian subject in need thereof, a therapeutically effective amount of a pharmaceutical composition comprising the compound of the invention, or an enantiomer, diastereomer, tautomer, or pharmaceutically acceptable salt, solvate, ester or pro-drug thereof that is effective in the treatment or prevention of type II diabetes mellitus thereof in a mammal including a human, and a pharmaceutically acceptable excipient, carrier, or diluent.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority to and the benefit of co-pending U.S. Provisional Patent Application No. 62 / 732,650, filed September 18, 2018, which is incorporated herein by reference in its entirety.

[0002] Technical Field The present invention relates generally to methods and related compositions for treating obesity and obesity-related conditions and disorders in a subject. [Background technology]

[0003] 2. Background of the Invention Worldwide, obesity represents a major threat to public health and results in a significant financial burden for many families and countries. 2 It is estimated that there are approximately 600 million obese adults worldwide, with a body mass index (BMI) of 100 or higher. Childhood obesity is of particular concern as it is often a neglected condition that can lead to long-term health problems. In the United States alone, adult obesity rates have increased significantly over the past few decades.

[0004] Obesity is a well-established risk factor for associated diseases, including type II diabetes, cardiovascular disease, nonalcoholic fatty liver disease (NAFLD), metabolic syndrome, polycystic ovarian syndrome (PCOS), obstructive sleep apnea, osteoarthritis, and several forms of cancer (endometrial, esophageal, gastric, liver, renal, multiple myeloma, meningioma, colorectal, gallbladder, breast, etc.). In societies where stereotypical views of obesity are prevalent, overweight people also face a myriad of psychological and social challenges and often suffer from low self-esteem, prejudice, and discrimination.

[0005] Clinically significant weight loss (>5%) can reduce risk factors for cardiovascular disease (CVD), delay or prevent the onset of various cancers and type II diabetes, and ultimately improve quality of life. However, most patients are unable to achieve sustained and clinically significant weight loss with current treatments.

[0006] Currently, bariatric surgery is the most effective treatment for obesity, but it has significant limitations including irreversibility of the procedure, perioperative and postoperative risks such as bleeding, anastomotic leakage, infection, internal hernia, nutritional deficiencies, postprandial hypoglycemia, mortality, and high financial costs.

[0007] There continues to be an unmet need for effective treatments and / or prevention methods for obesity and closely related conditions / disorders. Summary of the Invention [Means for solving the problem]

[0008] Summary of the Invention The present invention addresses these needs. The present invention provides novel methods of using the compounds of the present invention (embodiments detailed below). In one aspect, the present invention provides a method of treating or preventing obesity or overweight in a mammal, including a human, comprising administering to a mammalian subject in need thereof a compound of the present invention, or an enantiomer, diastereomer, tautomer or pharma- ceutically acceptable salt, solvate, ester or prodrug thereof, which is effective in treating or preventing obesity or overweight in a mammal, including a human. and administering to the patient a therapeutically effective amount of a pharmaceutical composition comprising a compound selected from the group consisting of ribozyme, ribozyme, and a pharma- ceutically acceptable excipient, carrier, or diluent.

[0009] In another aspect, the present invention provides a method of treating or preventing type II diabetes in a mammal, including a human, comprising administering to a mammalian subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising a compound of the present invention, or an enantiomer, diastereomer, tautomer or a pharma- ceutically acceptable salt, solvate, ester or prodrug thereof, and a pharma- ceutically acceptable excipient, carrier or diluent, which is effective in treating or preventing type II diabetes in a mammal, including a human.

[0010] In another aspect, the present invention provides a method of treating or preventing metabolic syndrome in a mammal, including a human, comprising administering to a mammalian subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising a compound of the present invention, or an enantiomer, diastereomer, tautomer or a pharma- ceutically acceptable salt, solvate, ester or prodrug thereof, and a pharma- ceutically acceptable excipient, carrier or diluent, which is effective in treating or preventing metabolic syndrome in a mammal, including a human.

[0011] In one aspect, the present invention relates to a method for treating obesity or at least one symptom or sign known to be associated with obesity or overweight (e.g., excessive weight, excess fat, over 30 kg / m 2 or more than 25kg / m 2 The present invention provides methods for reducing, ameliorating, or eliminating morbidity or mortality, including elevated BMI of 100 mg or more.

[0012] In one aspect, the invention provides a method for reducing, ameliorating, or eliminating at least one symptom or sign known to be associated with Type II diabetes (e.g., insulin resistance, frequent urination, increased thirst, and increased hunger), morbidity, or mortality.

[0013] In one aspect, the invention provides a method for reducing, ameliorating, or eliminating at least one symptom or sign known to be associated with metabolic syndrome (e.g., elevated blood pressure, elevated fasting plasma glucose, high serum triglycerides, low high density lipoprotein (HDL) levels, and elevated waist circumference), morbidity, or mortality.

[0014] In one feature, the method of the invention further comprises the further step of administering an additional agent selected from the group consisting of an insulin sensitizer, a diabetes agent, an agent or treatment for metabolic syndrome, and a weight loss agent as part of a combination regimen.

[0015] In various embodiments, the compound of the invention is one of formulas IX as described below in the detailed description of the invention.

[0016] In various embodiments, the compound of the invention is one of the following eight compounds: Compound 9, Compound 15-3, Compound 12, Compound 10-1, Compound 15-1, Compound 14-3, Compound 5, and Compound 7-1, as described in further detail below.

[0017] In further embodiments, the compounds of the present invention are any of the following 15 compounds described in more detail below: Compound 13-3-1, Compound 13-3-2, Compound 13-3-3, Compound 13-3-5, Compound 13-3-6, Compound 13-3-7, Compound 13-3-10, Compound 13-3-11, Compound 001, Compound 004, Compound 006, Compound 013, Compound 13-3-4, Compound 13-3-5, Compound 13-3-6, Compound 13-3-7, Compound 13-3-10, Compound 13-3-11, Compound 001, Compound 004, Compound 006, Compound 013, Compound 13-3-8, Compound 13-3-9, Compound 13-3-10, Compound 13-3-11, Compound 001, Compound 004, Compound 132, compound 133 and compound 134.

[0018] In yet another aspect, the present invention generally relates to pharmaceutical compositions comprising a compound disclosed herein, or a pharma- ceutically acceptable salt, solvate, ester, or prodrug thereof, and a pharma- ceutically acceptable excipient, carrier, or diluent, and uses thereof.

[0019] In one aspect, the present invention generally relates to methods of reducing weight or preventing weight gain in a patient in need thereof using one or more compositions disclosed herein. Treatment may further include the additional step of evaluating the success of the treatment by evaluating the subject / patient before and during treatment. [Brief description of the drawings]

[0020] [Figure 1A-B] Figures 1A-1D show: (1A) change in body weight during compound 14-3 treatment; (1B) body weight at the time of euthanasia; (1C) daily normalized caloric intake during compound 14-3 treatment; and (1D) daily normalized water intake during compound 14-3 treatment. [Figure 1C-D] Figures 1A-1D show: (1A) change in body weight during compound 14-3 treatment; (1B) body weight at the time of euthanasia; (1C) daily normalized caloric intake during compound 14-3 treatment; and (1D) daily normalized water intake during compound 14-3 treatment.

[0021] [Figure 2A] 2A-2C present in vivo animal data on: (2A) fecal triglyceride content, (2B) gene expression levels of molecular mediators of appetite regulation, and (2C) gene expression levels of markers for brown adipose tissue activation. [Figure 2B] 2A-2C present in vivo animal data on: (2A) fecal triglyceride content, (2B) gene expression levels of molecular mediators of appetite regulation, and (2C) gene expression levels of markers for brown adipose tissue activation. [Figure 2C] 2A-2C present in vivo animal data on: (2A) fecal triglyceride content, (2B) gene expression levels of molecular mediators of appetite regulation, and (2C) gene expression levels of markers for brown adipose tissue activation.

[0022] [Diagram 3]3A-3D present in vivo animal data for: (3A) epididymal fat pad weight, (3B) epididymal fat / body weight ratio, (3C) unilateral inguinal fat pad weight, and (3D) inguinal fat / body weight ratio.

[0023] [Figure 4A] 4A-4C present in vivo animal data for: (4A) eWAT visceral tissue, (4B) total number of adipocytes in the 200× field, and (4C) TGFc gene expression in eWAT. [Figure 4B-C] 4A-4C present in vivo animal data for: (4A) eWAT visceral tissue, (4B) total number of adipocytes in the 200× field, and (4C) TGFc gene expression in eWAT.

[0024] [Diagram 5] 5A-5B present in vivo animal data for: (5A) iWAT visceral tissue; and (5B) total number of adipocytes at 200× magnification.

[0025] [Figure 6] Figures 6A-6E present in vivo animal data on gene expression for: (6A) RAR-related orphan receptor alpha (RORA); (6B) acyl-coenzyme A dehydrogenase, C-4 to C-12 linear (ACADM); (6C) peroxisomal acyl-coenzyme A oxidase 1 (ACOX1); (6D) malonyl-CoA decarboxylase (MLYCD); and (6E) phosphoenolpyruvate carboxykinase (PEPCK).

[0026] [Figure 7] 7A-7C present in vivo animal data regarding: (7A) serum FGF21 levels; (7B) gene expression of FGF21; and (7C) serum leptin levels.

[0027] [Figure 8]8A-8B present in vivo animal data on: (8A) significant improvement of NAFLD following treatment with a compound of the invention (compound 14-3); and (8B) reduction in liver / body weight ratio following treatment with compound 14-3.

[0028] [Figure 9A-C] 9A-9E present in vivo animal data for: (9A) blood glucose levels during an oral glucose tolerance test (OGTT); (9B) area under the curve during an OGTT; (9C) blood glucose levels at 120 minutes during an OGTT; (9D) blood glucose levels during an intraperitoneal insulin tolerance test (ITT); and (9E) area under the curve during an ITT. [Fig. 9D-E] 9A-9E present in vivo animal data for: (9A) blood glucose levels during an oral glucose tolerance test (OGTT); (9B) area under the curve during an OGTT; (9C) blood glucose levels at 120 minutes during an OGTT; (9D) blood glucose levels during an intraperitoneal insulin tolerance test (ITT); and (9E) area under the curve during an ITT.

[0029] [Figure 10A-B] Figures 10A-10C present data on a study designed to see if the compounds of the invention have any effect on triglyceride accumulation in human hepatocyte cultures. Figures 10A-10C show quantification data on intracellular triglyceride accumulation when various embodiments of the compounds of the invention are used in each given sample. Compound 14-3 (*: DMSO vs. compound 14-3 in the corresponding culture medium; #: control medium (left two columns) vs. palmitoleic acid (POA) medium (right two columns); p<0.05) (Figure 10A); effects from nine other embodiments in POA medium compared to the effect of compound 14-3 (Figure 10B); effects from seven different embodiments in POA medium compared to the effect of compound 14-3 (Figure 10C). [Figure 10C]Figures 10A-10C present data on a study designed to see if the compounds of the invention have any effect on triglyceride accumulation in human hepatocyte cultures. Figures 10A-10C show quantification data on intracellular triglyceride accumulation when various embodiments of the compounds of the invention are used in each given sample. Compound 14-3 (*: DMSO vs. compound 14-3 in the corresponding culture medium; #: control medium (left two columns) vs. palmitoleic acid (POA) medium (right two columns); p<0.05) (Figure 10A); effects from nine other embodiments in POA medium compared to the effect of compound 14-3 (Figure 10B); effects from seven different embodiments in POA medium compared to the effect of compound 14-3 (Figure 10C). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0030] definition As used in this specification and claims, the singular forms "a," "an," or "the" include plural referents unless the context clearly dictates to the contrary. For example, the term "a cell" includes a plurality of cells, including mixtures of cells.

[0031] As used herein, the terms "about" or "approximately" when used in conjunction with a number refer to any number within 5, 10 or 15% of the referenced number.

[0032] As used herein, the term "subject" refers to any animal (e.g., mammal), including but not limited to humans, non-human primates, rodents, dogs, etc., that will be the recipient of a particular treatment. Typically, the terms "subject" and "patient" are used interchangeably herein in reference to human subjects.

[0033] As used herein, the term "obesity" refers to a medical condition in which body fat has accumulated in a manner that may or has adversely affected the health of a subject. One commonly used threshold for obesity is the Body Mass Index (BMI), calculated by dividing a person's weight by the square of their height, and is less than 25 kg / m 2 30 kg / m outside the Asia-Oceania Region and the WHO Western Pacific Region, where values ​​above this can be used. 2 or more (Kanazawa et al., World Review of Nutrition and Dietetics. 94:1-12 (2005)). In areas other than the Asia-Oceania region and the WHO Western Pacific region, the recommended daily intake is 25-30 kg / m 2 A BMI in this range is considered "overweight."

[0034] As used herein, the term "metabolic syndrome" or "insulin resistance syndrome" refers to the presence of at least three of the following five medical conditions: abdominal (central) obesity, elevated blood pressure, elevated fasting plasma glucose, high serum (serium) triglycerides, and low high-density lipoprotein (HDL) levels. Although the exact cause of the syndrome is still under investigation, it is believed that the following risk factors may contribute to the development of the syndrome: a high-sugar or high-calorie diet, obesity, insulin resistance, a sedentary lifestyle, stress, and aging. Various diagnostic criteria have been proposed by various organizations, with the main difference appearing to be the measure of central obesity. In an attempt to unify diagnostic criteria, several major organizations have agreed that abnormal findings in three of the five measurements should result in a clinical diagnosis of metabolic syndrome, while measurement of waist circumference remains a useful preliminary screening tool, but is not required (Alberti et al., Circulation 2009 Oct 20;120(16):1640-1645). Examples of a range of diagnostic cut points are: for elevated waist circumference: population- and country-specific definitions; for elevated triglycerides (or medical treatment therefor): ≥ 150 mg / dL (1.7 mmol / L); for lowered high-density lipoprotein cholesterol (HDL-C) (or medical treatment therefor): < 40 mg / dL (1.0 mmol / L) for men; < 50 mg / dL (1.3 mmol / L) for women; for elevated blood pressure triglycerides (or medical treatment therefor): systolic BP ≥ 130 and / or diastolic BP ≥ 85 mmHg; for elevated fasting glucose triglycerides (or medical treatment therefor): < 100 mg / dL.

[0035] As used herein, the terms "treat", "treating" and "treatment" have their ordinary and customary meanings and include one or more of blocking, ameliorating or reducing the severity, frequency and / or progression of symptoms of a disease or condition (e.g., diabetes), or inducing regression or stasis of a disorder or disease in a subject. Treatment refers to blocking, ameliorating, reducing or inhibiting by about 1% to about 100% relative to a subject in which the method of the invention is not performed. Preferably, the blocking, ameliorating, reducing or inhibiting is about 100%, 95%, 90%, 80%, 70%, 60%, 50%, 40%, 30%, 20%, 10% or 5% relative to a subject in which the method of the invention is not performed. Treatment can be for an existing condition or can be prophylactic against a future condition.

[0036] As used herein, the terms "inhibit," "inhibiting," and their grammatical equivalents, when used in the context of a biological activity, refer to the downregulation of a biological activity that may reduce or eliminate a targeted function, such as the production of a protein or the phosphorylation of a molecule. In embodiments, inhibition can refer to a reduction of about 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or 95% of the targeted activity. When used in the context of a disorder or disease, these terms refer to the success of preventing or significantly delaying the onset of symptoms, alleviating symptoms, or eliminating a disease, condition or disorder.

[0037] As used herein, the terms "administration", "administering", and the like, when used in the context of providing a pharmaceutical composition to a subject, generally refer to providing a subject with one or more pharmaceutical compositions comprising a compound of the present invention in combination with a suitable delivery vehicle by any means such that the administered compound achieves one or more of the intended biological effects for which the compound was administered. As non-limiting examples, the compositions can be administered parenterally, subcutaneously, intravenously, intracoronary, rectally, intramuscularly, intraperitoneally, transdermally, or via buccal delivery routes.

[0038] Definitions of specific functional groups and chemical terms are described in more detail below. General principles of organic chemistry, as well as specific functional moieties and reactivities, are described in "Organic Chemistry", by Thomas Sorrell, University Science Books, Sausalito: 2006.

[0039] Certain compounds of the present invention may exist in specific geometric or stereoisomeric forms. The present invention contemplates all such compounds, including cis and trans isomers, R- and S-enantiomers, diastereomers, (D)-isomers, (L)-isomers, racemic mixtures thereof, and other mixtures thereof, as falling within the scope of the present invention. Additional asymmetric carbon atoms may be present in substituents such as alkyl groups. All such isomers and mixtures thereof are intended to be included in the present invention.

[0040] Isomeric mixtures containing any of a variety of isomeric ratios can be utilized according to the present invention. For example, when only two isomers are combined, mixtures containing isomeric ratios of 50:50, 60:40, 70:30, 80:20, 90:10, 95:5, 96:4, 97:3, 98:2, 99:1 or 100:0 are contemplated by the present invention. Those skilled in the art will readily recognize that similar ratios are contemplated for more complex isomeric mixtures.

[0041] For example, if a particular enantiomer of a compound of the invention is desired, it may be prepared by asymmetric synthesis or by derivatization with a chiral auxiliary where the resulting diastereomeric mixture is separated and the auxiliary group is cleaved to provide the desired pure enantiomer. Alternatively, if the molecule contains a basic functional group such as amino or an acidic functional group such as carboxyl, a diastereomeric salt may be formed with an appropriate optically active acid or base, and the diastereomers thus formed may then be resolved by fractional crystallization or chromatographic methods well known in the art, followed by recovery of the pure enantiomer.

[0042] With the benefit of this disclosure, one of skill in the art will recognize that the synthetic methods as described herein may utilize a variety of protecting groups. The term "protecting group," as used herein, means that a particular functional moiety (e.g., O, S, or N) is temporarily blocked to allow a reaction to be selectively performed at another reactive site in a multifunctional compound. In preferred embodiments, the protecting group reacts selectively in good yield to give a protected substrate that is stable for the planned reaction; the protecting group should be selectively removable in good yield by a reagent that does not attack other functional groups, preferably a readily available non-toxic reagent; the protecting group forms a derivative that is easily separable (more preferably, without creating new asymmetric centers); the protecting group has minimal additional functionality to avoid further reactive sites. Oxygen, sulfur, nitrogen, and carbon protecting groups may be utilized. Examples of various protecting groups can be found in "Protective Groups in Organic Synthesis," 3rd Edition, Greene, TW and Wilson, J. Med., 1999, 144:131-135, 1999. Wuts, PG, Eds., John Wiley & Sons, New York: 1999.

[0043] It is understood that the compounds as described herein may be substituted with any number of substituents or functional moieties. Throughout the specification, groups and substituents thereof may be chosen to provide stable moieties and compounds.

[0044] As used herein, the term "effective amount" of an active agent refers to an amount sufficient to induce a desired biological response.As will be understood by those skilled in the art, the effective amount of the compound of the present invention may vary depending on factors such as the desired biological endpoint, the pharmacokinetics of the compound, the disease to be treated, the mode of administration and the patient.

[0045] As used herein, the term "pharmaceutically acceptable salt" means either a pharmaceutically acceptable acid addition salt or a pharmaceutically acceptable base addition salt of the presently disclosed compounds, which may be administered without any substantial undesired biological effects or without any deleterious interactions with any other components of the pharmaceutical composition in which it may be included.

[0046] The compounds of the present invention may form salts that are also within the scope of the present invention. Reference to the compounds of the present invention herein is understood to include reference to their salts, unless otherwise indicated. The term "salts" as used herein means acidic and / or basic salts formed with inorganic and / or organic acids and bases. Furthermore, when the compounds of the present invention contain both a basic moiety, such as, but not limited to, pyridine or imidazole, and an acidic moiety, such as, but not limited to, carboxylic acid, zwitterions ("internal salts") may be formed, which are included in the term "salts" as used herein. Although other salts are also useful, for example, in separation or purification steps that may be used during preparation, pharma-ceutically acceptable (i.e., non-toxic, physiologically acceptable) salts are preferred. Salts of the compounds of the present invention can be produced, for example, by reacting Compound I, II, or III with an equivalent amount of acid or base in a medium in which the salt precipitates, or in an aqueous medium (followed by lyophilization).

[0047] The compounds of the present invention that contain a basic moiety, such as, but not limited to, an amine or a pyridine or imidazole ring, can form salts with a variety of organic and inorganic acids. Exemplary acid addition salts include acetate (such as those formed with acetic acid or a trihaloacetic acid, e.g., trifluoroacetic acid), adipate, alginate, ascorbate, aspartate, benzoate, benzenesulfonate, bisulfate, borate, butyrate, citrate, camphorate, camphorsulfonate, cyclopentanepropionate, digluconate, dodecyl sulfate, ethanesulfonate, fumarate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, hydroxyl, hydroxypropyl ... These include ethanesulfonates (e.g., 2-hydroxyethanesulfonate), lactate, maleate, methanesulfonate, naphthalenesulfonate (e.g., 2-naphthalenesulfonate), nicotinate, nitrate, oxalate, pectinate, persulfate, phenylpropionate (e.g., 3-phenylpropionate), phosphate, picrate, pivalate, propionate, salicylate, succinate, sulfate (such as that formed with sulfuric acid), sulfonate, tartrate, thiocyanate, toluenesulfonate such as tosylate, undecanoate, and the like.

[0048] Compounds of the invention that contain an acid moiety, such as, but not limited to, carboxylic acids, can form salts with a variety of organic and inorganic bases. Exemplary base salts include ammonium salts, alkali metal salts such as sodium, lithium and potassium salts, alkaline earth metal salts such as calcium and magnesium salts, benzathine, dicyclohexylamine, hydrabamine (formed with N,N-bis(dehydroabietyl)ethylenediamine), Salts with organic bases (e.g., organic amines) such as N-methyl-D-glucamine, N-methyl-D-glycamide, t-butylamine, and the like, and salts with amino acids such as arginine, lysine, etc. Basic nitrogen-containing groups may be quaternized with agents such as lower alkyl halides (e.g., methyl, ethyl, propyl, and butyl chlorides, bromides, and iodides), dialkyl sulfates (e.g., dimethyl, diethyl, dibutyl, and cyamyl sulfate), long chain halides (e.g., decyl chlorides, bromides, and iodides, lauryl, myristyl, and stearyl), aralkyl halides (e.g., benzyl and phenethyl bromides), and others.

[0049] As used herein, the term "pharmaceutical acceptable ester" refers to an ester that hydrolyzes in vivo, including those that are easily decomposed in the human body to release the parent compound or its salt.Suitable ester groups include, for example, those derived from pharmaceutical acceptable aliphatic carboxylic acids, particularly alkanoic acids, alkenoic acids, cycloalkanoic acids and alkanedioic acids, in which each alkyl or alkenyl moiety advantageously has 6 or less carbon atoms.Specific examples of esters include formates, acetates, propionates, butyrates, acrylates and ethylsuccinates.

[0050] As used herein, the term "prodrug" refers to a pharmacological derivative of a parent drug molecule that requires either spontaneous or enzymatic biotransformation in an organism to release the active drug. For example, a prodrug is a variant or derivative of a compound of formula I that has a group that can be cleaved under certain metabolic conditions, resulting in a compound of formula I when cleaved. Such prodrugs then become pharmacologic in vivo when they undergo solvolysis or enzymatic degradation under physiological conditions. As used herein, prodrug compounds can be referred to as single, double, triple, etc., depending on the number of biotransformation steps required to release the active drug and the number of functional groups present in the precursor form.

[0051] Prodrug forms often offer advantages of solubility, tissue compatibility, or delayed release in the mammalian organism (Bundgard, Design of Prodrugs, pp. 7-9,21-24, Elsevier, Amsterdam 1985 and Silverman, The Organic Chemistry of Drug Design, pp. 117-119, 2001). and Drug Action, pp. 352-401, Academic Press, San Diego, Calif., 1992). Examples of prodrugs generally known in the art include, for example, Examples of prodrug derivatives include well-known acid derivatives such as esters prepared by reaction of a carboxylic acid with an appropriate alcohol, amides prepared by reaction of the parent acid compound with an amine, and basic groups reacting to form acylated basic derivatives. Of course, other prodrug derivatives may be combined with other features disclosed herein to enhance bioavailability. Thus, one skilled in the art will recognize that certain of the compounds disclosed herein that have free amino, amide, hydroxy, or carboxylic acid groups may be converted to prodrugs. Prodrugs include compounds having amino acid residues or polypeptide chains of two or more (e.g., 2, 3, or 4) amino acid residues covalently bonded by peptide bonds to free amino, hydroxy, or carboxylic acid groups of the compounds disclosed herein. Amino acid residues include the 20 naturally occurring amino acids, commonly designated by their three-letter code, and also 4-hydroxyproline, hydroxylysine, desmosine, isodesmosine, 3-methylhistidine, 4-methylhistidine, 5-methylhistidine, 6-methylhistidine, 7-methylhistidine, 8-methylhistidine, 9-methylhistidine, 10-methylhistidine, 11-methylhistidine, 12-methylhistidine, 13-methylhistidine, 14-methylhistidine, 15-methylhistidine, 16-methylhistidine, 17-methylhistidine, 18-methylhistidine, 19-methylhistidine, 20-methylhistidine, 21-methylhistidine, 22-methylhistidine, 23-methylhistidine, 24-methylhistidine, 25-methylhistidine, 26-methylhistidine, 27-methylhistidine, 28-methylhistidine, 29-methylhistidine, 30-methylhistidine, 31-methylhistidine, 32-methylhistidine, 33-methyl Prodrugs include cysteine, norvaline, β-alanine, γ-aminobutyric acid, citrulline homocysteine, homoserine, ornithine, and methionine sulfone. Prodrugs also include compounds having a carbonate, carbamate, amide, or alkyl ester moiety covalently bonded to any of the above substituents disclosed herein.

[0052] The term "pharmaceutically acceptable excipient, carrier or diluent" is used herein. "Acceptable" means a pharma- ceutically acceptable material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, solvent or encapsulating material, required to carry or transport a subject drug from one organ or part of the body to another, such as a pharmaceutical composition, a pharmaceutical composition, or a pharmaceutical composition that is suitable for use in a pharmaceutical composition, such as a pharmaceutical composition for use in a pharmaceutical composition, or a pharmaceutical composition for use in a pharmaceutical composition, such as ... Some examples of substances which can function as pharma- ceutically acceptable carriers are sugars such as lactose, glucose and sucrose; starches such as corn starch and potato starch; celluloses and their derivatives such as sodium carboxymethylcellulose, ethylcellulose and cellulose acetate; excipients such as powdered tragacanth, malt, gelatin, talc, cocoa butter and suppository waxes; oils such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; glycols such as propylene glycol; polyols such as glycerin, sorbitol, mannitol and polyethylene glycol; esters such as ethyl oleate and ethyl laurate; agar, buffers such as magnesium hydroxide and aluminum hydroxide, alginic acid, pyrogen-free water, isotonic saline, Ringer's solution, ethyl alcohol, phosphate buffers, and other non-toxic compatible substances used in pharmaceutical formulations. Wetting agents, emulsifiers and lubricants such as sodium lauryl sulfate, magnesium stearate, and polyethylene oxide-polypropylene oxide copolymers, as well as coloring agents, release agents, coating agents, sweetening, flavoring and perfuming agents, preservatives, and antioxidants may also be present in the composition.

[0053] As used herein, "C x ~C yThe term "C1-C6" generally refers to a group having from x to y carbon atoms. Thus, for example, "C1-C6" refers to a group having 1, 2, 3, 4, 5 or 6 carbon atoms, which includes C1-C2, C1-C3, C1-C4, C1-C5, C2-C3, C2-C4, C2-C5, C2-C6, and all similar combinations. 20 " etc. are similarly C1~C6, C1~C 12 and C3~C 12 and the like, including various combinations of between 1 and 20 (1 or more and 20 or less) carbon atoms.

[0054] As used herein, the term "alkyl" refers to a straight or branched chain alkane (hydrocarbon) group. Exemplary "alkyl" groups include methyl, ethyl, propyl, isopropyl, n-butyl, t-butyl, isobutyl, pentyl, hexyl, isohexyl, heptyl, 4,4-dimethylpentyl, octyl, 2,2,4-trimethylpentyl, nonyl, decyl, undecyl, dodecyl, and the like. "Substituted alkyl" refers to an alkyl group substituted with one or more substituents, preferably 1 to 4 substituents, at any available point of attachment. Exemplary substituents include one or more of the following groups: hydrogen, halogen (e.g., one halogen substituent or multiple halo substituents, in the latter case forming groups such as an alkyl group with CF3 or Cl3), cyano, nitro, CF3, OCF3, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, heterocycle, aryl, OR, aryl ... a , S.R. a , S(=O)R e , S(=O)2R e , P(=O)2R e , S(=O)2OR e , P(=O)2OR e , N.R. b R c , N.R. b S(=O)2R e , N.R. b P(=O)2R e , S(=O)2NR b R c, P(=O)2NR b R c , C(=O)OR d , C(=O)R a , C(=O)NR b R c ,OC(=O)R a ,OC(=O)NR b R c , N.R. b C(=O)OR e , N.R. d C(=O)NR b R c , N.R. d S(=O)2NR b R c , N.R. d P(=O)NR b R c , N.R. b C(=O)R a or NR b P(=O)R e Including, but not limited to, where R a is hydrogen, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, heterocycle or aryl; R b , R c and R d are independently hydrogen, alkyl, cycloalkyl, heterocycle, aryl, or optionally b and R c form a heterocycle or a substituted heterocycle together with the N to which they are attached, and R e is alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, heterocycle or aryl. In the above exemplary substituents, alkyl, cycloalkyl, alkenyl, alkynyl, cycloalkenyl, Groups such as alkyl, aryl, heterocycle and aryl may themselves be optionally substituted. x ~C y The term "alkyl" means a saturated straight or branched chain radical consisting essentially of x to y carbon atoms, where x is an integer from 1 to about 10 and y is an integer from about 2 to about 20.x ~C y The alkyl group is C1 to C 20 "Alkyl" and "C1-C 20 "Alkyl" means a saturated linear or branched radical consisting essentially of 1 to 20 carbon atoms and the corresponding number of hydrogen atoms. 20 Examples of alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, and dodecanyl. Of course, other C1-C 20 Alkyl groups will be readily apparent to those of skill in the art given the benefit of this disclosure. The term "alkyl" refers to any group selected from C1 to C6. 20 and preferably C1 to C 10 More preferably, it is C1 to C6, and further preferably, it is C1 to C6.

[0055] As used herein, the term "alkenyl" refers to a straight or branched chain hydrocarbon group having at least one carbon-carbon double bond. Exemplary such groups include ethenyl or allyl. "Substituted alkenyl" refers to an alkenyl group substituted with one or more substituents, preferably 1 to 4 substituents, at any available point of attachment. Exemplary substituents include, but are not limited to, alkyl or substituted alkyl, as well as those groups recited above as exemplary alkyl substituents. Exemplary substituents may themselves be optionally substituted. The term "alkenyl" refers to an alkenyl group having a C2-C 20 and preferably C2 to C 10 and more preferably C2 to C6.

[0056] As used herein, the term "alkynyl" refers to a straight or branched chain hydrocarbon group having at least one carbon-carbon triple bond. Exemplary such groups include ethynyl. "Substituted alkynyl" refers to an alkynyl group substituted with one or more substituents, preferably 1 to 4 substituents, at any available point of attachment. Exemplary substituents include, but are not limited to, alkyl or substituted alkyl, as well as those groups recited above as exemplary alkyl substituents. Exemplary substituents may themselves be optionally substituted. The term "alkynyl" refers to a C2-C6 alkyl group. 20 and preferably C2 to C 10 and more preferably C2 to C6.

[0057] As used herein, the term "aryl" refers to a cyclic aromatic hydrocarbon group having one to five aromatic rings, particularly a monocyclic or bicyclic group such as phenyl, biphenyl, or naphthyl. When containing two or more aromatic rings (e.g., bicyclic), the aromatic rings of the aryl group may be attached at one point (e.g., biphenyl) or fused (e.g., naphthyl, phenanthrenyl, etc.). "Substituted aryl" or "substituted phenyl" refers to an aryl or phenyl group substituted at any point of attachment with one or more substituents, preferably one to three substituents. Exemplary substituents include, but are not limited to, nitro, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, cyano, alkyl or substituted alkyl, as well as the groups recited above as exemplary alkyl substituents. Exemplary substituents may themselves be optionally substituted. Exemplary substituents also include fused ring groups, particularly fused cycloalkyl, fused cycloalkenyl, fused heterocycle, or fused aryl, where the aforementioned cycloalkyl, cycloalkenyl, heterocycle, and aryl substituents can themselves be optionally substituted.

[0058] As used herein, the term "cycloalkyl" refers to a fully saturated cyclic hydrocarbon group having 1 to 4 rings and 3 to 10 carbons per ring. Exemplary such groups are cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclobutyl, cyclohexyl ... cycloheptyl, and the like. "Substituted cycloalkyl" refers to a cycloalkyl group substituted at any available point of attachment with one or more substituents, preferably 1 to 4 substituents. Exemplary substituents include, but are not limited to, nitro, cyano, alkyl or substituted alkyl, as well as the groups recited above as exemplary alkyl substituents. Exemplary substituents may themselves be optionally substituted. Exemplary substituents also include spiro-linked or fused ring substituents, particularly spiro-linked cycloalkyl, spiro-linked cycloalkenyl, spiro-linked heterocycle (excluding heteroaryl), fused cycloalkyl, fused cycloalkenyl, fused heterocycle, or fused aryl, the foregoing cycloalkyl, cycloalkenyl, heterocycle, and aryl substituents may themselves be optionally substituted. The term "cycloalkyl" refers to any group having a C3-C6 carbon atom, ... 10 and preferably C3 to C8, and more preferably C3 to C6.

[0059] As used herein, the term "cycloalkenyl" refers to a partially unsaturated cyclic hydrocarbon group containing 1 to 4 rings and 3 to 10 carbons per ring. Exemplary such groups include cyclobutenyl, cyclopentenyl, cyclohexenyl, and the like. "Substituted cycloalkenyl" refers to a cycloalkenyl group substituted with one or more substituents, preferably 1 to 4 substituents, at any available point of attachment. Exemplary substituents include, but are not limited to, nitro, cyano, alkyl or substituted alkyl, as well as the groups recited above as exemplary alkyl substituents. Exemplary substituents may themselves be optionally substituted. Exemplary substituents also include spiro-linked or fused ring substituents, particularly spiro-linked cycloalkyl, spiro-linked cycloalkenyl, spiro-linked heterocycle (excluding heteroaryl), fused cycloalkyl, fused cycloalkenyl, fused heterocycle, or fused aryl, the foregoing cycloalkyl, cycloalkenyl, heterocycle, and aryl substituents may themselves be optionally substituted. The term "cycloalkenyl" refers to a C3-C6 alkyl group. 10 and preferably C3 to C8, and more preferably C3 to C6.

[0060] As used herein, the term "heterocycle" or "heterocyclic" refers to fully saturated or partially or fully unsaturated, including aromatic (i.e., "heteroaryl") cyclic groups (e.g., 4- to 7-membered monocyclic, 7- to 11-membered bicyclic, or 8- to 16-membered tricyclic systems) having at least one heteroatom in at least one carbon atom-containing ring. Each ring of the heteroatom-containing heterocyclic group may have 1, 2, 3, or 4 heteroatoms selected from nitrogen, oxygen, and / or sulfur atoms, the nitrogen and sulfur heteroatoms optionally being oxidized, and the nitrogen heteroatom optionally being quaternized. (The term "heteroarylium" refers to a heteroaryl group having a quaternary nitrogen atom, and thus a positive charge.) The heterocyclic group may be attached to any heteroatom or carbon atom of the ring or ring system of the remainder of the molecule. Exemplary monocyclic heterocyclic groups are azetidinyl, pyrrolidinyl, pyrrolyl, pyrazolyl, oxetanyl, pyrazolinyl, imidazolyl, imidazolinyl, imidazolidinyl, oxazolyl, oxazolidinyl, isoxazolinyl, isoxazolyl, thiazolyl, thiadiazolyl, thiazolidinyl, isothiazolyl, isothiazolidinyl, furyl, tetrahydrofuryl, thienyl, oxadiazolyl, piperidinyl, piperazinyl, 2-oxopipera Exemplary bicyclic heterocyclic groups include indolyl, isoindolyl, benzothiazolyl, benzoxazolyl, benzoxadiazolyl, benzothienyl, benzo[d][1,3]dioxolyl, 2,3-dihydrobenzo[b][1,4]dioxinyl, quinoxadiazolyl ...b][1,4]dioxinyl, quinoxadiazolyl, benzo[b][1,4]dioxinyl, quinoxadiazolyl, benzo[b][1,4]dioxinyl, quinoxadiazolyl, benzo[b][1,4]dioxinyl, quinoxadiazolyl, benzo[b][1,4]dioxinyl, quinoxadiazolyl, benzo Included are lysinyl, quinolinyl, tetrahydroisoquinolinyl, isoquinolinyl, benzimidazolyl, benzopyranyl, indolizinyl, benzofuryl, benzofurazanyl, chromonyl, coumarinyl, benzopyranyl, cinnolinyl, quinoxalinyl, indazolyl, pyrrolopyridyl, furopyridinyl (such as furo[2,3-c]pyridinyl, furo[3,2-b]pyridinyl or furo[2,3-b]pyridinyl), dihydroisoindolyl, dihydroquinazolinyl (such as 3,4-dihydro-4-oxoquinazolinyl), triazinylazepinyl, tetrahydroquinolinyl, and the like. Exemplary tricyclic heterocyclic groups include carbazolyl, benzidolyl, phenanthrolinyl, acridinyl, phenanthridinyl, xanthenyl, and the like.

[0061] As used herein, "substituted heterocycle" and "substituted heterocyclic" (e.g., "substituted heteroaryl") refer to a heterocycle or heterocyclic group substituted with one or more substituents, preferably 1 to 4 substituents, at any available point of attachment. Exemplary substituents include, but are not limited to, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, nitro, oxo (i.e., =O), cyano, alkyl or substituted alkyl, heterocycle or substituted heterocycle, aryl or substituted aryl, as well as those groups recited above as exemplary alkyl substituents. Exemplary substituents may themselves be optionally substituted. Exemplary substituents also include spiro-linked or fused ring substituents, particularly spiro-linked cycloalkyl, spiro-linked cycloalkenyl, spiro-linked heterocycle (excluding heteroaryl), fused cycloalkyl, fused cycloalkenyl, fused heterocycle, or fused aryl, at any available point of attachment or points, and the foregoing cycloalkyl, cycloalkenyl, heterocycle, and aryl substituents may themselves be optionally substituted.

[0062] As used herein, the term "halogen" means fluorine (F), chlorine (Cl), bromine (Br) or iodine (I).

[0063] The term "carbocyclic" refers to aromatic or non-aromatic 3- to 7-membered monocyclic and 7- to 11-membered bicyclic groups in which all atoms of the ring or rings are carbon atoms. "Substituted carbocyclic" refers to a carbocyclic group substituted with one or more substituents, preferably 1 to 4 substituents, at any available point of attachment. Exemplary substituents are nitro, cyano, OR, aryl ... a (R a is as defined above), as well as those groups recited above as exemplary cycloalkyl substituents. The exemplary substituents may themselves be optionally substituted.

[0064] Unless otherwise noted, any heteroatom with unsatisfied valences is presumed to have sufficient hydrogen atoms to satisfy the valences.

[0065] Isotopically labeled compounds are also within the scope of this disclosure.As used herein, "isotopically labeled compounds" refers to compounds disclosed herein, including pharmaceutical salts and prodrugs thereof, each as described herein, in which one or more atoms are replaced by atoms with atomic masses or mass numbers different from those usually found in nature.Examples of isotopes that can be incorporated into compounds disclosed herein include, respectively, pharmaceutical salts and prodrugs thereof, each as described herein. 2 H, 3 H, 13 C. 14 C. 15 N, 18 O. 17 O. 31 P, 32 P, 35 S, 18 F and 36 Included are isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, fluorine and chlorine, such as Cl.

[0066] By isotopically labelling the compounds disclosed herein, the compounds may be useful in drug and / or substrate tissue distribution assays. 3 H) and carbon-14 ( 14 C) labeled compounds are particularly preferred due to their ease of preparation and detectability. 2 Substitution with heavier isotopes, such as H, can confer certain therapeutic advantages resulting from greater metabolic stability (e.g., increased in vivo half-life or reduced dosage requirements) and therefore may be preferred in some circumstances. The isotopically labeled compounds disclosed herein, including pharmaceutical salts, esters and prodrugs thereof, can be prepared by any means known in the art.

[0067] In addition, the usual abundance of hydrogen ( 1 Substitution of heavier isotopes, such as deuterium, for hydrogen (H) may provide certain therapeutic advantages (e.g., resulting from improved absorption, distribution, metabolism and / or excretion (ADME) properties) and may create drugs with improved efficacy, safety and / or tolerability. 12 C 13 C. See WO 2007 / 005643, WO 2007 / 005644, WO 2007 / 016361 and WO 2007 / 016431.

[0068] The term "hydrogen" refers to all hydrogen isotopes, including protium and deuterium. In a given composition, the hydrogen molecules may be all protium, all deuterium, or a mixture of both, unless otherwise specified.

[0069] All stereoisomers (e.g., cis and trans isomers) and optical isomers (e.g., R and S enantiomers) of the compounds disclosed herein, as well as racemic, diastereomeric and other mixtures of such isomers, are within the scope of the disclosure.

[0070] The compounds, salts, esters, prodrugs, hydrates and solvates disclosed herein may exist in several tautomeric forms, including enol and imine forms, and keto and enamine forms, as well as geometric isomers and their mixtures.Tautomers exist as mixtures of soluble tautomer sets.In solid form, one tautomer is usually predominant.Although one tautomer may be described, all tautomers are within the scope of this disclosure.

[0071] Atropisomers are also within the scope of this disclosure, by which is meant compounds that can be separated into isomers with restricted rotation.

[0072] The compounds of the invention, after their preparation, are preferably isolated and purified to obtain compositions containing an amount equal to or greater than 95% by weight ("substantially pure") for use or preparation as described herein. In certain embodiments, the compounds of the invention are greater than 99% pure.

[0073] Solvates of the compounds of the invention are also contemplated herein. Solvates of the compounds of the invention include, for example, hydrates. Detailed Description of the Invention

[0074] The present invention provides compounds, as well as pharmaceutical compositions containing such compounds described herein, or enantiomers, diastereomers, tautomers, or pharma- ceutically acceptable salts, solvates, esters or prodrugs thereof, and their uses in the treatment and prevention of obesity or overweight and diseases and disorders closely related thereto, such as type II diabetes and metabolic syndrome, in mammalian subjects.

[0075] Specifically, the present invention provides a pharmaceutical composition comprising any compound of the invention described herein, or a pharma- ceutically acceptable salt, solvate, ester or prodrug thereof, and a pharma- ceutically acceptable excipient, carrier or diluent.

[0076] The present invention also provides a method of treating or preventing obesity or overweight, and diseases and disorders closely related thereto, such as type II diabetes and metabolic syndrome, in a mammalian subject, including a human, comprising administering to a mammalian subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising any of the compounds of the present invention described herein, or an enantiomer, diastereomer, tautomer, or a pharma- ceutically acceptable salt, solvate, ester or prodrug thereof, and a pharma- ceutically acceptable excipient, carrier or diluent, which is effective in treating or preventing obesity or overweight, and diseases and disorders closely related thereto, such as type II diabetes and metabolic syndrome, in a mammal, including a human.

[0077] In one aspect, the invention provides methods that result in one or more of the following health benefits from successfully treating or preventing obesity or overweight and, optionally, their comorbidities: reduction in weight and BMI; improved insulin sensitivity; improved liver function; and improvement in at least one of the five diagnostic criteria of metabolic syndrome.

[0078] In some embodiments, the present invention generally relates to the use of compounds of formula I for the therapeutic or prophylactic treatment of obesity or overweight, as well as co-morbidities closely related thereto, including type II diabetes and metabolic syndrome. [ka] or an enantiomer, diastereomer, tautomer, or a pharma- ceutically acceptable salt or solvate thereof. wherein the symbols have the following meanings, independently selected for each occurrence: R1 is hydrogen, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, aryl or substituted aryl, OR a , S.R. a , S(=O)2R e , S(=O)2OR e , C(=O)OR d , C(=O)R a or C(=O)NR b R c and R2 is a heterocycle or substituted heterocycle, aryl or substituted aryl; R3 is hydrogen, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, heterocycle or substituted heterocycle, aryl or substituted aryl; R4, R7, and R8 are each independently hydrogen, halogen, cyano, nitro, CF3, OCF3, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, aryl or substituted aryl, OR a , S.R. a , S(=O)R e , S(=O)2R e , P(=O)2R e , S(=O)2OR e , P(=O)2OR e , N.R. b R c , N.R. b S(=O)2R e , N.R. b P(=O)2R e , S(=O)2NR b R c , P(=O)2NR b R c , C(=O)OR e , C( =O)R a , C(=O)NRb R c ,OC(=O)R a ,OC(=O)NR b R c , N.R. b C(=O)OR e , N.R. d C(=O)NR b R c , N.R. d S(=O)2NR b R c , N.R. d P(=O)NR b R c , N.R. b C(=O)R a or NR b P(=O)2R e and R5 is alkyl or substituted alkyl, heterocycle or substituted heterocycle, aryl or substituted aryl, amino or substituted amino; R6 is hydrogen, halogen, cyano, nitro, CF3, OCF3, alkyl or substituted alkyl, heterocycle or substituted heterocycle, aryl or substituted aryl, or OR; a and R a is hydrogen, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, or aryl or substituted aryl; R b , R c and R d are independently hydrogen, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, heterocycle or substituted heterocycle, or aryl or substituted aryl, or optionally, b and R c together with the N to which they are attached form a heterocyclic ring or a substituted heterocyclic ring, R eis alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, or aryl or substituted aryl.

[0079] In some embodiments, the present invention generally relates to the use of a compound of formula II for the therapeutic or prophylactic treatment of obesity or overweight, as well as co-morbidities closely related thereto, including type II diabetes and metabolic syndrome. [ka] or an enantiomer, diastereomer, tautomer, or a pharma- ceutically acceptable salt or solvate thereof. wherein the symbols have the following meanings and are independently selected for each occurrence: Het is a 5- or 6-membered aromatic ring containing at least one heteroatom selected from N, O and S; R1 is hydrogen, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, aryl or substituted aryl, OR a , S.R. a , S(=O)2R e , S(=O)2OR e , C(=O)OR d , C(=O)R a or C(=O)NR b R c and R3 and R 10 are each independently hydrogen, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, heterocycle or substituted heterocycle, aryl or substituted aryl; R4, R7, and R8 each independently represent hydrogen, halogen, cyano, nitro, CF3, OCF3, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl, aryl or substituted cycloalkenyl, heterocycle or substituted heterocycle, aryl or substituted aryl, OR a , S.R. a , S(=O)R e , S(=O)2R e , P(=O)2R e , S(=O)2OR e , P(=O)2OR e , N.R. b R c , N.R. b S(=O)2R e , N.R. b P(=O)2R e , S(=O)2NR b R c , P(=O)2NR b R c , C(=O)OR e , C(=O)R a , C(=O)NR b R c ,OC(=O)R a ,OC(=O)NR b R c , N.R. b C(=O)OR e , N.R. d C(=O)NR b R c , N.R. d S(=O)2NR b R c , N.R. d P(=O)NR b R c , N.R. b C(=O)R a or NR b P(=O)2R e and R5 is alkyl or substituted alkyl, heterocycle or substituted heterocycle, aryl or substituted aryl, amino or substituted amino; R6 and R9 are each independently hydrogen, halogen, cyano, nitro, CF3, OCF3, alkyl or substituted alkyl, heterocycle or substituted heterocycle, aryl or substituted aryl, or ORa; R 14 and R 15 are independently hydrogen, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, heterocycle or substituted heterocycle, or aryl or substituted aryl, or optionally, 14 and R 15 together with the N to which they are attached form a heterocyclic ring or a substituted heterocyclic ring, Ra is hydrogen, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, or aryl or substituted aryl; R b , R c and R d are independently hydrogen, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, heterocycle or substituted heterocycle, or aryl or substituted aryl, or optionally, b and R c together with the N to which they are attached form a heterocyclic ring or a substituted heterocyclic ring, R e is alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, or aryl or substituted aryl.

[0080] In some embodiments, the present invention generally relates to the use of a compound of formula III for the therapeutic or prophylactic treatment of obesity or overweight, as well as co-morbidities closely related thereto, including type II diabetes and metabolic syndrome. [ka] or an enantiomer, diastereomer, tautomer, or a pharma- ceutically acceptable salt or solvate thereof. wherein the symbols have the following meanings and are independently selected for each occurrence: Het is a 5- or 6-membered aromatic ring containing at least one heteroatom selected from N, O and S; R1 is hydrogen, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, aryl or or substituted aryl, OR a , S.R. a , S(=O)2R e , S(=O)2OR e , C(=O)OR d , C(=O)R a or C(=O)NR b R c and R3 and R 10 are each independently hydrogen, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, heterocycle or substituted heterocycle, aryl or substituted aryl; R4, R7, and R8 each independently represent hydrogen, halogen, cyano, nitro, CF3, OCF3, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, aryl or substituted aryl, OR a , S.R. a , S(=O)R e , S(=O)2R e , P(=O)2R e , S(=O)2OR e , P(=O)2OR e , N.R. b R c , N.R. b S(=O)2R e , N.R.b P(=O)2R e , S(=O)2NR b R c , P(=O)2NR b R c , C(=O)OR e , C(=O)R a , C(=O)NR b R c ,OC(=O)R a ,OC(=O)NR b R c , N.R. b C(=O)OR e , N.R. d C(=O)NR b R c , N.R. d S(=O)2NR b R c , N.R. d P(=O)NR b R c , N.R. b C(=O)R a or NR b P(=O)2R e and R5 is alkyl or substituted alkyl, heterocycle or substituted heterocycle, aryl or substituted aryl, amino or substituted amino; R6 and R9 are each independently hydrogen, halogen, cyano, nitro, CF3, OCF3, alkyl or substituted alkyl, heterocycle or substituted heterocycle, aryl or substituted aryl, or OR a and R 11 is hydrogen or C 1~4 is alkyl, R 12 and R 13 are independently hydrogen, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, heterocycle or substituted heterocycle, or aryl or substituted aryl, or 12 and R 13 optionally form a heterocyclic or substituted heterocyclic ring together with the N to which they are attached; n is an integer selected from 2, 3, 4, 5, and 6; R a is hydrogen, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, or aryl or substituted aryl; R b , R c and R d are independently hydrogen, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, heterocycle or substituted heterocycle, or aryl or substituted aryl, or b and R c optionally form a heterocyclic or substituted heterocyclic ring together with the N to which they are attached; R e is alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, or aryl or substituted aryl.

[0081] In some embodiments, the present invention generally relates to the use of a compound of formula IV for the therapeutic or prophylactic treatment of obesity or overweight, as well as co-morbidities closely related thereto, including type II diabetes and metabolic syndrome. [ka] or an enantiomer, diastereomer, tautomer, or a pharma- ceutically acceptable salt or solvate thereof. wherein the symbols have the following meanings and are independently selected for each occurrence: Het is a 5- or 6-membered aromatic ring containing at least one heteroatom selected from N, O and S; R1 is hydrogen, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, aryl or substituted aryl, OR a , S.R. a , S(=O)2R e , S(=O)2OR e , C(=O)OR d , C(=O)R a or C(=O)NR b R c and R3 and R 10 are each independently hydrogen, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, heterocycle or substituted heterocycle, aryl or substituted aryl; R4, R7, and R8 each independently represent hydrogen, halogen, cyano, nitro, CF3, OCF3, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, aryl or substituted aryl, OR a , S.R. a , S(=O)R e , S(=O)2R e , P(=O)2R e , S(=O)2OR e , P(=O)2OR e , N.R. b R c , N.R. b S(=O)2R e , N.R. b P(=O)2R e , S(=O)2NR b R c , P(=O)2NR b R c , C(=O)OR e , C(=O)R a , C(=O)NR b R c ,OC(=O)R a ,OC(=O)NR b Rc , N.R. b C(=O)OR e , N.R. d C(=O)NR b R c , N.R. d S(=O)2NR b R c , N.R. d P(=O)NR b R c , N.R. b C(=O)R a or NR b P(=O)2R e and R5 is alkyl or substituted alkyl, heterocycle or substituted heterocycle, aryl or substituted aryl, amino or substituted amino; R6 and R9 are each independently hydrogen, halogen, cyano, nitro, CF3, OCF3, alkyl or substituted alkyl, heterocycle or substituted heterocycle, aryl or substituted aryl, or OR a and R 14 and R 15 are independently hydrogen, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, heterocycle or substituted heterocycle, or aryl or substituted aryl, or 14 and R 15 optionally form a heterocyclic or substituted heterocyclic ring together with the N to which they are attached; R a is hydrogen, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, or aryl or substituted aryl; R b , R c and R d are independently hydrogen, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, heterocycle or substituted heterocycle, or aryl or substituted aryl, or b and R care combined with the N to which they are attached to form a complex. optionally forming a monocyclic or substituted heterocyclic ring, R e is alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, or aryl or substituted aryl.

[0082] In some embodiments, the present invention generally relates to the use of a compound of formula V for the therapeutic or prophylactic treatment of obesity or overweight, as well as co-morbidities closely related thereto, including type II diabetes and metabolic syndrome. [ka] or an enantiomer, diastereomer, tautomer, or a pharma- ceutically acceptable salt or solvate thereof. wherein the symbols have the following meanings and are independently selected for each occurrence: R1 is hydrogen, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, aryl or substituted aryl, OR a , S.R. a , S(=O)2R e , S(=O)2OR e , C(=O)OR d , C(=O)R a or C(=O)NR b R c and R3 and R 10 are each independently hydrogen, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, heterocycle or substituted heterocycle, aryl or substituted aryl; R4, R7, and R8 each independently represent hydrogen, halogen, cyano, nitro, CF3, OCF3, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, aryl or substituted aryl, OR a , S.R. a , S(=O)R e , S(=O)2R e , P(=O)2R e , S(=O)2OR e , P(=O)2OR e , N.R. b R c , N.R. b S(=O)2R e , N.R. b P(=O)2R e , S(=O)2NR b R c , P(=O)2NR b R c , C(=O)OR e , C(=O)R a , C(=O)NR b R c ,OC(=O)R a ,OC(=O)NR b R c , N.R. b C(=O)OR e , N.R. d C(=O)NR b R c , N.R. d S(=O)2NR b R c , N.R. d P(=O)NR b R c , N.R. b C(=O)R a or NR b P(=O)2R e and R5 is substituted alkyl, heterocycle or substituted heterocycle, aryl or substituted aryl, amino or substituted amino; R6 and R9 are each independently hydrogen, halogen, cyano, nitro, CF3, OCF3, alkyl or substituted alkyl, heterocycle or substituted heterocycle, aryl or substituted aryl, or OR a and R 11 is hydrogen or C 1~4 is alkyl, R 12 and R 13 are independently hydrogen, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, heterocycle or substituted heterocycle, or aryl or substituted aryl, or 12 and R 13 together with the N to which they are attached optionally forming a heterocyclic ring or a substituted heterocyclic ring, n is an integer selected from 2, 3, 4, 5, and 6; R a is hydrogen, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, or aryl or substituted aryl; R b , R c and R d are independently hydrogen, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, heterocycle or substituted heterocycle, or aryl or substituted aryl, or b and R c optionally form a heterocyclic or substituted heterocyclic ring together with the N to which they are attached; R e is alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, or aryl or substituted aryl.

[0083] In various embodiments, the compound of the invention is one of the following eight compounds: [ka] [ka]

[0084] Item 1. In one embodiment, the present invention generally relates to a compound of formula VI for the therapeutic or prophylactic treatment of obesity or overweight, as well as co-morbidities closely related thereto, including type II diabetes and metabolic syndrome. [ka] or an enantiomer, diastereomer, tautomer, or a pharma- ceutically acceptable salt or solvate thereof. During the ceremony, R1 is hydrogen, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, aryl or substituted aryl. ROLL, OR a , S.R. a , S(=O)2R e , S(=O)2OR e , C(=O)OR d , C(=O)R a or C(=O)NR b R c and R2 is a monocyclic or bicyclic heterocycle or substituted heterocycle, aryl or substituted aryl; R3 is hydrogen, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, heterocycle or substituted heterocycle, aryl or substituted aryl, halogen, -OR a , -C(O)R a , -C(O)OR a , -NR a R b , or S(O)NRa R b R4, R5, R6 and R7 are each independently hydrogen, halogen, cyano, nitro, trihalomethyl, OCF3, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, aryl or substituted aryl, OR a , S.R. a , S(=O)R e , S(=O)2R e , P(=O)2R e , S(=O)2OR e , P(=O)2OR e , N.R. b R c , N.R. b S(=O)2R e , N.R. b P(=O)2R e , S(=O)2NR b R c , P(=O)2NR b R c , C(=O)OR e , C(=O)R a , C(=O)NR b R c ,OC(=O)R a ,OC(=O)NR b R c , N.R. b C(=O)OR e , N.R. d C(=O)NR b R c , N.R. d S(=O)2NR b R c , N.R. d P(=O)NR b R c , N.R. b C(=O)R a or NR b P(=O)2R e and T is O, S or R a and U, V and W are each independently carbon, N, O or S; X, Y, Z and A are each independently carbon or N, with the proviso that the ring in which X, Y, Z and A occur is aromatic; provided that one of R4, R5, R6 and R7 is a substituted heterocycle or a substituted aryl, and when X, Y, Z or A is a heteroatom, R4, R5, R6 or R7 is absent, and the substituted heterocycle and substituted aryl in R4, R5, R6 and R7 are each selected from the following groups: [ka] and During the ceremony Q-2 is a heterocycle, C(=O)NR b R c or aryl, R n’ , R n’’ and R n’’’ each independently represents hydrogen, halogen, cyano, nitro, trihalomethyl, OCF3, alkyl or substituted alkyl, OR a , S.R. a , C(=O)R a , C(=O)OR a , NH2, S(O)2NH2, NR b R c , a heterocycle or a substituted heterocycle or an aryl or a substituted aryl; R a is hydrogen, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, or aryl or substituted aryl; R b , R c and R d are independently hydrogen, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, heterocycle or substituted heterocycle, or aryl or substituted aryl, or optionally, b and R c together with the N to which they are attached form a heterocycle or a substituted heterocycle; Re is hydrogen, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl, aryl or substituted cycloalkenyl, heterocycle or substituted heterocycle, or aryl or substituted aryl.

[0085] Item 2. The compound according to item 1, wherein T is O or S: [ka]

[0086] Item 3. The compound according to item 2, wherein T is O: [ka]

[0087] Item 4. The compound according to item 2, wherein V is carbon: [ka]

[0088] Item 5. The compound according to Item 2, wherein W is N: [ka]

[0089] Item 6. The compound according to item 5, wherein T is O and W is N: [ka]

[0090] Item 7. The compound according to item 4, wherein T is O and V is carbon: [ka]

[0091] Item 8. The compound according to item 1, wherein U is carbon, V is carbon, W is N, and T is O: [ka]

[0092] Item 9. The compound according to any one of items 1 to 8, wherein each of X, Y, Z and A is carbon.

[0093] Item 10. The compound according to any one of items 1 to 9, wherein R1 is hydrogen.

[0094] Item 11. R2 is [ka] wherein Q-1 is a heterocycle or an aryl; R 2’ , R 2’’ , R 2’’’ and R 2’’’’ are each independently absent, hydrogen, halogen, cyano, nitro, trihalomethyl, OCF3, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, heterocycle or substituted heterocycle, aryl or substituted aryl, or OR a , N.R. b R c , N.R. b S(=O)2R e , N.R. b P(=O)2R e , S(=O)2NR b R c , P(=O)2NR b R c , C(=O)OR e , C(=O)R a , C(=O)NR b R c ,OC(=O)R a ,OC(=O)NR b R c , N.R. b C(=O)OR e , N.R. d C(=O)NRb R c , N.R. d S(=O)2NR b R c , N.R. d P(=O)NR b R c , N.R. b C(=O)R a or NR b P(=O)2R e The compound according to any one of items 1 to 10,

[0095] Item 12. The compound according to item 10 or 11, wherein one of X, Y, Z and A is a heteroatom.

[0096] Item 13. The compound according to any one of items 10 to 12, wherein Q-1 is heteroaryl.

[0097] Item 13'. The compound according to any one of Items 10 to 12, wherein Q-1 is phenyl.

[0098] Item 14. The compound according to any one of items 13, wherein Q-1 is selected from the group consisting of pyrrole, furan, thiophene, pyridine, pyrimidine, pyrazine, pyridazine, imidazole, indole, pyrrolopyridinone, pyridone, pyrrolidine, pyridinone, piperidine and pyrroloazepinone.

[0099] Item 15. The compound according to item 14, wherein Q-1 is selected from the group consisting of pyrrole, furan, thiophene, pyridine, pyrimidine, pyrazine, pyridazine, imidazole, indole, and pyrrolopyridinone.

[0100] Item 16. The compound according to item 15, wherein Q-1 is pyrrole.

[0101] Item 17. The compound according to item 13, wherein Q-1 is pyridone, pyrrolidine, pyridinone or piperidine.

[0102] Item 18. The compound according to item 17, wherein Q-1 is a pyridone or pyridinone.

[0103] Item 19.R 2’ , R 2’’ , R 2’’’ and R 2’’’’ are independently absent, hydrogen, alkyl, substituted alkyl, substituted heterocycle, substituted aryl, C(=O)OR e or C(=O)NR b R c and During the ceremony R b and R c are independently hydrogen, alkyl, substituted alkyl, substituted heterocycle, or optionally, b and R c form a heterocycle or a substituted heterocycle together with the N to which they are attached; R e is hydrogen, The compound according to any one of items 11 to 18.

[0104] Item 20.R 2’ , R 2’’ , R 2’’’ and R 2’’’’ One of them is C(=O)NR b R c where R b is hydrogen, R c is NR bn R cn (R in the formula bn and R cn is alkyl, or optionally, bn and R cn are taken together with the N to which they are attached to form a substituted heterocycle, said heterocycle being piperidine or morpholine, or optionally R b and R c together with the N to which they are attached form a substituted heterocycle, said heterocycle being piperidine or morpholine; R2’ , R 2’’ , R 2’’’ and R 2’’’’ 20. The compound according to item 19, wherein two of are independently alkyl and the other is hydrogen.

[0105] Item 21.R 2’ , R 2’’ , R 2’’’ and R 2’’’’ One of them is C(=O)NR b R c where: NR b R c 21. The compound according to item 20, wherein is 2-(di-ethylamino)ethyl, amino, 2-pyrrolidinoethylamino, 4-methylpiperazinyl or morpholino.

[0106] Item 21'. Q-1 is pyrrole, R 2’ , R 2’’ , R 2’’’ and R 2’’’’ does not exist and R 2’ , R 2’’ , R 2’’’ and R 2’’’’ Two of the are alkyl (e.g., methyl), and R 2’ , R 2’’ , R 2’’’ and R 2’’’’ One of them is C(=O)NR b R c Item 17. The compound according to item 16, wherein

[0107] Item 21''.R b is hydrogen, R c is NR bn R cn (wherein R bn and R cn is alkyl, or optionally, bn and R cn The compound according to item 21', wherein together with the N to which they are attached form a substituted heterocycle, said heterocycle being piperidine or morpholine.

[0108] Item 21'''.NR b R c is 2-(diethylamino)ethyl, amino or 2- The compound according to item 21'', which is pyrrolidinoethylamino.

[0109] Item 21''''. If necessary, R b and R c together with the N to which they are attached form a heterocycle or a substituted heterocycle.

[0110] Item 21'''''.NR b R c is 4-methylpiperazinyl or morpholino.

[0111] Item 22. R4, R5, R6 and R7 are each independently hydrogen, halogen, cyano, nitro, alkyl or substituted alkyl, OR a , N.R. b R c , C(=O)OR e , C(=O)R a , C(=O)NR b R c ,or [ka] 22. The compound according to any one of items 1 to 21, wherein

[0112] Item 23. R4, R5, R6 and R7 are each independently hydrogen, halogen, cyano, nitro, alkyl, OR a , N.R. b R c , C(=O)OR e , C(=O)R a , C(=O)NR b R c (In the ceremony R a is hydrogen, or alkyl or substituted alkyl; R band R c are independently hydrogen, or alkyl or substituted alkyl; R e is alkyl or substituted alkyl, optionally substituted with one or more substituents selected from the group consisting of hydroxy, amino, nitro, cyano, halogen, alkoxy, alkylcarbonyl, alkoxycarbonyl, aminocarbonyl, aryl, cycloalkyl, and heterocycle; and [ka] 23. The compound according to any one of items 1 to 22, wherein

[0113] Item 24. One of R4, R5, R6 and R7 is [ka] and the others of R4, R5, R6 and R7 are each independently hydrogen. 24. The compound according to any one of claims 23.

[0114] Item 25. The compound according to item 24, wherein Q-2 is selected from the group consisting of pyrrole, furan, thiophene, imidazole, pyrazole, oxazole, isoxazole, thiazole, isothiazole, triazole, thiadiazole, oxadiazole, pyrrolidine, piperidine, azepane, tetrahydrofuran, oxane, oxepane, indole, indolinone, indazole, benzothiazole, quinoline, quinazoline, quinoxaline, imidazopyridine, imidazopyridazine, pyrazolopyridine, pyrazolopyrimidine, phthalazinone and phenyl.

[0115] Item 26. The compound according to item 25, wherein Q-2 is selected from the group consisting of pyrrole, furan, thiophene, imidazole, pyrazole, oxazole, isoxazole, thiazole, isothiazole, triazole, thiadiazole, oxadiazole, pyrrolidine, piperidine, azepane, tetrahydrofuran, oxane, oxepane, indole, indolinone, indazole, benzothiazole, quinoline, quinazoline, quinoxaline, imidazopyridine, imidazopyridazine, pyrazolopyridine, pyrazolopyrimidine and phthalazinone.

[0116] Item 27. The compound according to item 26, wherein Q-2 is selected from the group consisting of thiophene, imidazole, oxazole, thiazole, thiadiazole, piperidine and pyrazole.

[0117] Item 27'. The compound according to item 26, wherein Q-2 is selected from the group consisting of indole, indolinone, indazole, benzothiazole, quinoline, quinazoline, quinoxaline, imidazopyridine, imidazopyridazine, pyrazolopyridine, pyrazolopyrimidine and phthalazinone.

[0118] Item 28. The compound according to Item 27, wherein Q-2 is thiazole.

[0119] Item 29. The compound according to Item 27, wherein Q-2 is imidazole.

[0120] Item 30. The compound according to Item 27, wherein Q-2 is piperidine.

[0121] Item 31. The compound according to Item 27, wherein Q-2 is pyrazole.

[0122] Item 32.R n’is pyrrolidinyl, piperidinyl, azepanyl, tetrahydrofuranyl, oxanyl, oxepanyl, pyranyl, phenyl, thiophenyl, pyrazinyl, pyrimidinyl, pyridazinyl or pyridyl, optionally wherein the piperidinyl, pyranyl, phenyl, thiophenyl, pyrazinyl, pyrimidinyl, pyridazinyl and pyridyl are selected from the group consisting of halogen, cyano, nitro, alkyl or substituted alkyl, OR a , N.R. b R c , C(=O)OR e , C(=O)R a or C(=O)NR b R c (wherein R a is hydrogen or alkyl or substituted alkyl; R b and R c are independently hydrogen, or alkyl or substituted alkyl, and R e is alkyl or substituted alkyl, optionally substituted with one or more substituents selected from the group consisting of hydroxy, amino, nitro, cyano, halogen, alkoxy, alkylcarbonyl, alkoxycarbonyl, aminocarbonyl, aryl, cycloalkyl, and heterocycle; R n’’ and R n’’’ are independently hydrogen, or alkyl or substituted alkyl (optionally, the substituted alkyl is one or more selected from the group consisting of hydroxy, amino, nitro, cyano, halogen, alkoxy, alkylcarbonyl, alkoxycarbonyl, aminocarbonyl, aryl, cycloalkyl, and heterocycle); 26. The compound according to any one of items 22 to 25, wherein the compound is substituted with more than one substituent.

[0123] Item 32'.R n’ , R n’’ and R n’’’ 26. The compound according to any one of items 22 to 25, wherein is independently hydrogen, alkyl or methoxy.

[0124] Item 32''.R n’ , Rn’’ and R n’’’ and each are hydrogen.

[0125] Item 33.R n’ pyrrolidinyl, piperidinyl, tetrahydrofuranyl, pyranyl, phenyl, pyrazinyl, pyrimidinyl or pyridyl, whereby the piperidinyl, pyranyl, phenyl, pyrazinyl, pyrimidinyl and pyridyl are optionally selected from the group consisting of halogen, cyano, alkyl or substituted alkyl, OR a ORC(=O)OR e (wherein R a is hydrogen, or alkyl or substituted alkyl; R e is alkyl or substituted alkyl (optionally substituted alkyl with one or more substituents selected from the group consisting of hydroxy, amino, nitro, cyano, halogen, alkoxy, alkylcarbonyl, alkoxycarbonyl, aminocarbonyl, aryl, cycloalkyl, and heterocycle); R n’’ and R n’’’ is independently hydrogen, alkyl or amino.

[0126] Item 33'.R n’ is phenyl or substituted phenyl, R n’’ and R n’’’ is independently hydrogen, or alkyl or amino.

[0127] Item 34.R n’’ and R n’’’ is independently hydrogen or alkyl.

[0128] Item 35.Q-2 is based on the following criteria: [ka] 34. The compound according to item 32 or 33, selected from the group consisting of:

[0129] Item 36.Q-2 is based on the following criteria: [ka] 34. The compound according to item 32 or 33, selected from the group consisting of:

[0130] Item 37. The following [ka] The compound according to any one of items 1, selected from the group consisting of:

[0131] In another aspect, the present invention generally relates to the use of a compound of formula VII for the therapeutic or prophylactic treatment of obesity or overweight, and co-morbidities closely related thereto, including type II diabetes and metabolic syndrome. [ka] or an enantiomer, diastereomer, tautomer, or a pharma- ceutically acceptable salt or solvate thereof. During the ceremony R1 is hydrogen, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, aryl or substituted aryl, OR a , S.R. a , S(=O)2R e , S(=O)2OR e , C(=O)OR d , C(=O)R a or C(=O)NR b R c and R3 is hydrogen, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, heterocycle or substituted heterocycle, aryl or substituted aryl, halogen, -OR a , -C(O)R a , -C(O)OR a , -NRa R b , or S(O)NR a R b R4, R6 and R7 are each independently hydrogen, halogen, cyano, nitro, trihalomethyl, OCF3, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, aryl or substituted aryl, OR a , S.R. a , S(=O)R e , S(=O)2R e , P(=O)2R e , S(=O)2OR e , P(=O)2OR e , N.R. b R c , N.R. b S(=O)2R e , N.R. b P(=O)2R e , S(=O)2NR b R c , P(=O)2NR b R c , C(=O)OR e , C(=O)R a , C(=O)NR b R c ,OC(=O)R a ,OC(=O)NR b R c , N.R. b C(=O)OR e , N.R. d C(=O)NR b R c , N.R. d S(=O)2NR b R c , N.R. d P(=O)NR b R c , N.R. b C(=O)R a or NR b P(=O)2R e and X, Z and A are each independently carbon or N, with the proviso that the ring in which X, Z and A occur is aromatic; Q-1 and Q-2 are independently a heterocycle, C(=O)NR b R c or aryl, R 2’ , R 2’’ , R 2’’’ and R 2’’’’ each independently is absent, hydrogen, halogen, cyano, nitro, trihalomethyl, OCF3, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, heterocycle or substituted heterocycle, aryl or substituted aryl, or OR a , N.R. b R c , N.R. b S(=O)2R e , N.R. b P(=O)2R e , S(=O)2NR b R c , P(=O)2NR b R c , C(=O)OR e , C(=O)R a , C(=O)NR b R c ,OC(=O)R a ,OC(=O)NR b R c , N.R. b C(=O)OR e , N.R. d C(=O)NR b R c , N.R. d S(=O)2NR b R c , N.R. d P(=O)NR b R c , N.R. b C(=O)R a or NR b P(=O)2R e and R 5’ , R 5’’ and R 5’’’ are each independently hydrogen, halogen, cyano, nitro, CF3, OCF3, alkyl or substituted alkyl, ORa , S.R. a , C(=O)R a , C(=O)OR a , NH2, S(O)2NH2, NR b R c , heterocycle or substituted heterocycle is a cyclic ring, an aryl ring, or a substituted aryl ring; During the ceremony R a is hydrogen, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, or aryl or substituted aryl; R b , R c and R d are independently hydrogen, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, heterocycle or substituted heterocycle, or aryl or substituted aryl, or optionally, b and R c together with the N to which they are attached form a heterocycle or a substituted heterocycle; R e is hydrogen, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, or aryl or substituted aryl.

[0132] In some embodiments, the compound of formula (VII) wherein each of X, Z and A is carbon. In some embodiments, the compound of formula (VII) wherein one of X, Z and A is a heteroatom.

[0133] In some embodiments, the compound of formula (VII) has the formula (VII-a): [ka] wherein R1, R 2’ , R2’’ , R 2’’’ , R 2’’’’ , R3, R4, R 5’ , R 5’’ , R 5’’’ , R6, R7, X, Q-1 and Q-2 are as defined above.

[0134] In some embodiments, the compound of formula (VII) has the formula (VII-b): [ka] wherein R 2’ , R 2’’ , R 2’’’ are each independently absent, hydrogen, halogen, cyano, nitro, trihalomethyl, OCF3, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, heterocycle or substituted heterocycle, aryl or substituted aryl, or OR a , N.R. b R c , N.R. b S(=O)2R e , N.R. b P(=O)2R e , S(=O)2NR b R c , P(=O)2NR b R c , C(=O)OR e , C(=O)R a , C(=O)NR b R c ,OC(=O)R a ,OC(=O)NR b R c , N.R. b C(=O)OR e , N.R. d C(=O)NR b R c , N.R. d S(=O)2NR b R c , N.R. d P(=O)NR b R c , N.R. b C(=O)R a Or NRb P(=O)2R e and R 2’’’’ is hydrogen, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, aryl or substituted aryl, OR a , S.R. a , S(=O)2R e , S(=O)2OR e , C(=O)OR d , C(=O)R a , C(=O)NR b R c and R1, R3, R4, R 5’ , R 5’’ , R 5’’’ , R6, R7, X and Q-2 are the same as defined above.

[0135] In some embodiments, the compound of formula (VII-b) is C. In some embodiments, the compound of formula (VII-b) is N. In some embodiments, the compound of formula (VII-b) is R 2’’’’ is H. In some embodiments, R 2’’ and R 2’’’ is independently hydrogen. 2’’ and R 2’’’ is independently methyl.

[0136] In some embodiments, the compound of formula (VII) has the formula (VII-c): [ka] wherein R1, R 2’ , R 2’’ , R 2’’’ , R 2’’’’ , R3, R4, R 5’ , R 5’’, R6, R7, X and Q-1 are the same as defined above.

[0137] In some embodiments, the compound of formula (VII) has the formula (VII-d): [ka] wherein X is C or N; R 2’ , R 2’’ , R 2’’’ are each independently absent, hydrogen, halogen, cyano, nitro, trihalomethyl, OCF3, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, heterocycle or substituted heterocycle, aryl or substituted aryl, or OR a , N.R. b R c , N.R. b S(=O)2R e , N.R. b P(=O)2R e , S(=O)2NR b R c , P(=O)2NR b R c , C(=O)OR e , C(=O)R a , C(=O)NR b R c ,OC(=O)R a ,OC(=O)NR b R c , N.R. b C(=O)OR e , N.R. d C(=O)NR b R c , N.R. d S(=O)2NR b R c , N.R. d P(=O)NR b R c , N.R. b C(=O)R a Or NR b P(=O)2R e and R 2’’’’is hydrogen, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, aryl or substituted aryl, OR a , S.R. a , S(=O)2R e , S(=O)2OR e , C(=O)OR d , C(=O)R a , C(=O)NR b R c and R1, R3, R4, R 5’ , R 5’’ , R6 and R7 are defined as above.

[0138] In some embodiments, the compound of formula (VII) has the formula (VII-e): [ka] wherein Z is C or N; R1, R 2’ , R 2’’ , R 2’’’ , R 2’’’’ , R3, R4, R 5’ , R 5’’ , R 5’’’ , R6, R7, Q-1 and Q-2 are as defined above.

[0139] In some embodiments, the compound of formula (VII) has the formula (VII-f): [ka] wherein Z is C or N; R 2’ , R 2’’ , R 2’’’are each independently absent, hydrogen, halogen, cyano, nitro, trihalomethyl, OCF3, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, heterocycle or substituted heterocycle, aryl or substituted aryl, or OR a , N.R. b R c , N.R. b S(=O)2R e , N.R. b P(=O)2R e , S(=O)2NR b R c , P(=O)2NR b R c , C(=O)OR e , C(=O)R a , C(=O)NR b R c ,OC(=O)R a ,OC(=O)NR b R c , N.R. b C(=O)OR e , N.R. d C(=O)NR b R c , N.R. d S(=O)2NR b R c , N.R. d P(=O)NR b R c , N.R. b C(=O)R a Or NR b P(=O)2R e and R 2’’’’ is hydrogen, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, aryl or substituted aryl, OR a , S.R. a , S(=O)2R e , S(=O)2OR e , C(=O)OR d , C(=O)R a , C(=O)NR b R c and R1, R3, R4, R 5’ , R 5’’ , R 5’’’ , R6, R7 and Q-2 are defined as above.

[0140] In some embodiments, the compound of formula (VII-f) is C. In some embodiments, the compound of formula (VII-f) is N. In some embodiments, the compound of formula (VII-f) is R 2’’’’ is H. In some embodiments, R 2’’ and R 2’’’ is independently hydrogen. In some embodiments, R 2’’ and R 2’’’ is independently methyl.

[0141] In some embodiments, the compound of formula (VII) has the formula (VII-g): [ka] wherein Z is C or N; R1, R 2’ , R 2’’ , R 2’’’ , R 2’’’’ , R3, R4, R 5’ , R 5’’ , R6, R7 and Q-1 are defined as above.

[0142] In some embodiments, the compound of formula (VII) has the formula (VII-h): [ka] wherein Z is C or N; R 2’ , R 2’’ , R 2’’’are each independently absent, hydrogen, halogen, cyano, nitro, trihalomethyl, OCF3, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, heterocycle or substituted heterocycle, aryl or substituted aryl, or OR a , N.R. b R c , N.R. b S(=O)2R e , N.R. b P(=O)2R e , S(=O)2NR b R c , P(=O)2NR b R c , C(=O)OR e , C(=O)R a , C(=O)NR b R c ,OC(=O)R a ,OC(=O)NR b R c , N.R. b C(=O)OR e , N.R. d C(=O)NR b R c , N.R. d S(=O)2NR b R c , N.R. d P(=O)NR b R c , N.R. b C(=O)R a Or NR b P(=O)2R e and R 2’’’’ is hydrogen, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, aryl or substituted aryl, OR a , S.R. a , S(=O)2R e , S(=O)2OR e , C(=O)OR d , C(=O)R a , C(=O)NR b R c and R1, R3, R4, R 5’ , R 5’’、 R6 and R7 are defined as above.

[0143] In some embodiments, the compound of formula (VII) has the formula (VII-i): [ka] wherein A is C or N; R1, R 2’ , R 2’’ , R 2’’’ , R 2’’’’ , R3, R4, R 5’ , R 5’’ , R 5’’’ , R6, R7, Q-1 and Q-2 are as defined above.

[0144] In some embodiments, the compound of formula (VII) has the formula (VII-j): [ka] wherein A is C or N; R 2’ , R 2’’ , R 2’’’ are each independently absent, hydrogen, halogen, cyano, nitro, trihalomethyl, OCF3, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, heterocycle or substituted heterocycle, aryl or substituted aryl, or OR a , N.R. b R c , N.R. b S(=O)2R e , N.R. b P(=O)2R e , S(=O)2NR b R c , P(=O)2NR b R c , C(=O)OR e , C(=O)R a , C(=O)NR b Rc ,OC(=O)R a ,OC(=O)NR b R c , N.R. b C(=O)OR e , N.R. d C(=O)NR b R c , N.R. d S(=O)2NR b R c , N.R. d P(=O)NR b R c , N.R. b C(=O)R a Or NR b P(=O)2R e and R 2’’’’ is hydrogen, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, aryl or substituted aryl, OR a , S.R. a , S(=O)2R e , S(=O)2OR e , C(=O)OR d , C(=O)R a , C(=O)NR b R c and R1, R3, R4, R 5’ , R 5’’ , R 5’’’ , R6, R7 and Q-2 are defined as above.

[0145] In some embodiments, the compound of formula (VII-j) is A. In some embodiments, the compound of formula (VII-j) is a substituted or unsubstituted aryl group. 2’’’’ is H. In some embodiments, R 2’’ and R 2’’’ is independently hydrogen. In some embodiments, R 2’’ and R 2’’’is each independently methyl.

[0146] In some embodiments, the compound of formula (VII) has the formula (VII-k): [ka] wherein A is C or N; R1, R 2’ , R 2’’ , R 2’’’ , R 2’’’’ , R3, R4, R 5’ , R 5’’ , R6, R7 and Q-1 are defined as above.

[0147] In some embodiments, the compound of formula (VII) has the formula (VII-l): [ka] wherein A is C or N; R 2’ , R 2’’ , R 2’’’ are each independently absent, hydrogen, halogen, cyano, nitro, trihalomethyl, OCF3, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, heterocycle or substituted heterocycle, aryl or substituted aryl, or OR a , N.R. b R c , N.R. b S(=O)2R e , N.R. b P(=O)2R e , S(=O)2NR b R c , P(=O)2NR b R c , C(=O)OR e , C(=O)R a , C(=O)NR b R c ,OC(=O)R a ,OC(=O)NR b R c, N.R. b C(=O)OR e , N.R. d C(=O)NR b R c , N.R. d S(=O)2NR b R c , N.R. d P(=O)NR b R c , N.R. b C(=O)R a Or NR b P(=O)2R e and R 2’’’’ is hydrogen, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, aryl or substituted aryl, OR a , S.R. a , S(=O)2R e , S(=O)2OR e , C(=O)OR d , C(=O)R a , C(=O)NR b R c and R1, R3, R4, R 5’ , R 5’’、 R6 and R7 are defined as above.

[0148] In some embodiments, the compound of formula (VII) has the formula (VII-m): [ka] wherein R1, R 2’ , R 2’’ , R 2’’’ , R 2’’’’ , R3, R4, R 5’ , R 5’’ , R 5’’’ , R6 and R7 are defined as above.

[0149] In some embodiments, the compound of formula (VII) has the formula (VII-n): [ka] wherein R1, R 2’ , R 2’’ , R 2’’’ , R 2’’’’ , R3, R4, R 5’ , R 5’’ , R 5’’’ , R6 and R7 are defined as above.

[0150] In some embodiments, the compound of formula (VII) has the formula (VII-o): [ka] wherein R1, R 2’ , R 2’’ , R 2’’’ , R 2’’’’ , R3, R4, R 5’ , R 5’’ , R 5’’’ , R6 and R7 are defined as above.

[0151] In some embodiments, the present invention generally relates to the use of a compound of formula VIII for the therapeutic or prophylactic treatment of obesity or overweight, as well as co-morbidities closely related thereto, including type II diabetes and metabolic syndrome. [ka] or an enantiomer, diastereomer, tautomer, or a pharma- ceutically acceptable salt or solvate thereof. During the ceremony R1 is hydrogen, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, aryl or substituted aryl, OR a , S.R.a , S(=O)2R e , S(=O)2OR e , C(=O)OR d , C(=O)R a or C(=O)NR b R c and R3 is hydrogen, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, heterocycle or substituted heterocycle, aryl or substituted aryl, halogen, -OR a , -C(O)R a , -C(O)OR a , -NR a R b , S(O)NR a R b and R4, R5 and R7 each independently represent hydrogen, halogen, cyano, nitro, trihalomethyl, OCF3, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, aryl or substituted aryl, OR a , S.R. a , S(=O)R e , S(=O)2R e , P(=O)2R e , S(=O)2OR e , P(=O)2OR e , N.R. b R c , N.R. b S(=O)2R e , N.R. b P(=O)2R e , S(=O)2NR b R c , P(=O)2NR b R c , C(=O)OR e , C(=O)R a , C(=O)NR b R c ,OC(=O)R a ,OC(=O)NR b R c , N.R. b C(=O)ORe , N.R. d C(=O)NR b R c , N.R. d S(=O)2NR b R c , N.R. d P(=O)NR b R c , N.R. b C(=O)R a or NR b P(=O)2R e and X, Y and A are each independently carbon or N, with the proviso that the ring in which X, Y and A reside is aromatic; Q-1 and Q-2 are independently a heterocycle, C(=O)NR b R c or aryl, R 2’ , R 2’’ , R 2’’’ and R 2’’’’ each independently is absent, hydrogen, halogen, cyano, nitro, trihalomethyl, OCF3, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, heterocycle or substituted heterocycle, aryl or substituted aryl, or OR a , N.R. b R c , N.R. b S(=O)2R e , N.R. b P(=O)2R e , S(=O)2NR b R c , P(=O)2NR b R c , C(=O)OR e , C(=O)R a , C(=O)NR b R c ,OC(=O)R a ,OC(=O)NR b R c , N.R. b C(=O)OR e , N.R. d C(=O)NR b R c , N.R. d S(=O)2NR b R c , N.R. d P(=O)NR b R c , N.R. b C(=O)R a or NR b P(=O)2R e and R 6’ , R 6’’ and R 6’’’ each independently represents hydrogen, halogen, cyano, nitro, trihalomethyl, OCF3, alkyl or substituted alkyl, OR a , S.R. a , C(=O)R a , C(=O)OR a , NH2, S(O)2NH2, a heterocycle or a substituted heterocycle or an aryl or a substituted aryl; During the ceremony R a is hydrogen, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, or aryl or substituted aryl; R b , R c and R d are independently hydrogen, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, heterocycle or substituted heterocycle, or aryl or substituted aryl, or optionally, b and R c together with the N to which they are attached form a heterocycle or a substituted heterocycle; R e is hydrogen, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, or aryl or substituted aryl.

[0152] In some embodiments, the present invention generally relates to the use of a compound of formula IX for the therapeutic or prophylactic treatment of obesity or overweight, as well as co-morbidities closely related thereto, including type II diabetes and metabolic syndrome. [ka] or an enantiomer, diastereomer, tautomer, or a pharma- ceutically acceptable salt or solvate thereof, wherein R1 is hydrogen, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, aryl or substituted aryl, OR a , S.R. a , S(=O)2R e , S(=O)2OR e , C(=O)OR d , C(=O)R a or C(=O)NR b R c and R3 is hydrogen, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, heterocycle or substituted heterocycle, aryl or substituted aryl, halogen, -OR a , -C(O)R a , -C(O)OR a , -NR a R b or S(O)NR a R b and R4, R5 and R6 each independently represent hydrogen, halogen, cyano, nitro, trihalomethyl, OCF3, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl, cycloalkyl ... alkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, aryl or substituted aryl, OR a , S.R. a , S(=O)R e , S(=O)2R e, P(=O)2R e , S(=O)2OR e , P(=O)2OR e , N.R. b R c , N.R. b S(=O)2R e , N.R. b P(=O)2R e , S(=O)2NR b R c , P(=O)2NR b R c , C(=O)OR e , C(=O)R a , C(=O)NR b R c ,OC(=O)R a ,OC(=O)NR b R c , N.R. b C(=O)OR e , N.R. d C(=O)NR b R c , N.R. d S(=O)2NR b R c , N.R. d P(=O)NR b R c , N.R. b C(=O)R a or NR b P(=O)2R e and X, Y and Z are each independently carbon or N, with the proviso that the ring in which X, Y and Z occur is aromatic; Q-1 and Q-2 each independently represent a heterocycle, C(=O)NR b R c or aryl, R 2’ , R 2’’ , R 2’’’ and R 2’’’’ each independently is absent, hydrogen, halogen, cyano, nitro, trihalomethyl, OCF3, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, heterocycle or substituted heterocycle, aryl or substituted aryl, or OR a , N.R. b Rc , N.R. b S(=O)2R e , N.R. b P(=O)2R e , S(=O)2NR b R c , P(=O)2NR b R c , C(=O)OR e , C(=O)R a , C(=O)NR b R c ,OC(=O)R a ,OC(=O)NR b R c , N.R. b C(=O)OR e , N.R. d C(=O)NR b R c , N.R. d S(=O)2NR b R c , N.R. d P(=O)NR b R c , N.R. b C(=O)R a or NR b P(=O)2R e and R 7’ , R 7’’ and R 7’’’ each independently represents hydrogen, halogen, cyano, nitro, trihalomethyl, OCF3, alkyl or substituted alkyl, OR a , S.R. a , C(=O)R a , C(=O)OR a , NH2, S(O)2NH2, a heterocycle or a substituted heterocycle or an aryl or a substituted aryl; During the ceremony R a is hydrogen, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, or aryl or substituted aryl; R b , R c and Rd are independently hydrogen, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, heterocycle or substituted heterocycle, or aryl or substituted aryl, or optionally, b and R c together with the N to which they are attached form a heterocycle or a substituted heterocycle; R e is hydrogen, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, or aryl or substituted aryl.

[0153] In some embodiments, the present invention generally relates to the use of a compound of formula X for the therapeutic or prophylactic treatment of obesity or overweight, as well as co-morbidities closely related thereto, including type II diabetes and metabolic syndrome. [ka] or an enantiomer, diastereomer, tautomer, or a pharma- ceutically acceptable salt or solvate thereof. During the ceremony R1 is hydrogen, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, aryl or substituted aryl, OR a , S.R. a , S(=O)2R e , S(=O)2OR e , C(=O)OR d , C(=O)R a or C(=O)NR b R c and R3 is hydrogen, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, heterocycle or substituted heterocycle, aryl or substituted aryl, halogen, -OR a, -C(O)R a , -C(O)OR a , -NR a R b or S(O)NR a R b and R5, R6 and R7 each independently represent hydrogen, halogen, cyano, nitro, trihalomethyl, OCF3, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, aryl or substituted aryl, OR a , S.R. a , S(=O)R e , S(=O)2R e , P(=O)2R e , S(=O)2OR e , P(=O)2OR e , N.R. b R c , N.R. b S(=O)2R e , N.R. b P(=O)2R e , S(=O)2NR b R c , P(=O)2NR b R c , C(=O)OR e , C(=O)R a , C(=O)NR b R c ,OC(=O)R a ,OC(=O)NR b R c , N.R. b C(=O)OR e , N.R. d C(=O)NR b R c , N.R. d S(=O)2NR b R c , N.R. d P(=O)NR b R c , N.R. b C(=O)R a or NR b P(=O)2R e and Y, Z and A are each independently carbon or N, with the proviso that the ring in which Y, Z and A occur is aromatic; Q-1 and Q-2 are independently a heterocycle, C(=O)NR b R c or aryl, R 2’ , R 2’’ , R 2’’’ and R 2’’’’ each independently is absent, hydrogen, halogen, cyano, nitro, trihalomethyl, OCF3, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, heterocycle or substituted heterocycle, aryl or substituted aryl, or OR a , N.R. b R c , N.R. b S(=O)2R e , N.R. b P(=O)2R e , S(=O)2NR b R c , P(=O)2NR b R c , C(=O)OR e , C(=O)R a , C(=O)NR b R c ,OC(=O)R a ,OC(=O)NR b R c , N.R. b C(=O)OR e , N.R. d C(=O)NR b R c , N.R. d S(=O)2NR b R c , N.R. d P(=O)NR b R c , N.R. b C(=O)R a or NR b P(=O)2R e and R 4’ , R 4’’ and R 4’’’each independently represents hydrogen, halogen, cyano, nitro, trihalomethyl, OCF3, alkyl or substituted alkyl, OR a , S.R. a , C(=O)R a , C(=O)OR a , NH2, S(O)2NH2, heterocycle or substituted heterocycle or aryl or substituted aryl; During the ceremony R a is hydrogen, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, or aryl or substituted aryl; R b , R c and R d are independently hydrogen, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, heterocycle or substituted heterocycle, or aryl or substituted aryl, or optionally, b and R c together with the N to which they are attached form a heterocycle or a substituted heterocycle; R e is hydrogen, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, or aryl or substituted aryl.

[0154] In various embodiments, the compound of the invention is one of the following 15 compounds: [ka] [ka] synthesis

[0155] Exemplary methods for preparing the compounds of the invention are described in the sections that follow, but the invention is not intended to be limited thereto.

[0156] In the following exemplary methods for chemically synthesizing the compounds of the invention, the starting materials and the intermediates of the reactions can be isolated and purified if desired using conventional techniques, including but not limited to filtration, distillation, crystallization, chromatography, and the like.

[0157] The materials of the present invention can be characterized by conventional means, including, but not limited to, physical constants and spectral data. The reactions are carried out in solvents appropriate to the reagents and materials employed and suitable for the transformations being effected. Representative examples include, but are not limited to, tetrahydrofuran, dimethylformamide, methanol, ethanol, water, dimethylformamide, chloroform, dichloromethane, hexane, toluene, 1,4-dioxane, or ethyl acetate.

[0158] Unless specified, reactions described herein were carried out over a temperature range of about -78°C to about 150°C at atmospheric pressure.

[0159] For heating, any method can be used depending on the reagents and target materials, typical examples include, but are not limited to, a water bath, an oil bath, a water bath or a microwave reactor.

[0160] In the present invention, the compound of formula VI can be prepared from known compounds by the following Preparation Methods I-II, methods similar to the following Preparation Methods, or by combining syntheses known to those skilled in the art as necessary. Preparation method

[0161] Compounds of formula VI may be synthesized by the following method. [ka]

[0162] In the scheme, R1, R2, R3, R4, R5, R6, R7, T, U, V, W, X, Y, Z, A, R n’ , R n’’ , R n’’’ and Q-2 is VI-1 and VIII-1, in which R4, R5, R6 and R7 are [ka] As defined above for formula V1, except that: J is a metal-containing group such as boronic acid, boronic acid pinacol ester, trifluoroborane, organotin, zinc halide, magnesium halide, organosilicon, and organolithium. K is a leaving group such as Cl, Br, I, and OTf. ·Preparation method I

[0163] The compounds of the present invention can be synthesized by the following methods.

[0164] Of the compounds of formula VI, compound VI-3 or a pharma- ceutically acceptable salt thereof is prepared by the following method. [ka]

[0165] In the Schemes, the symbols have the same meaning as defined above.

[0166] The compound of formula VI-1 can be reacted with a compound of formula VI-2 in the presence of a transition metal catalyst (representative examples include, but are not limited to, tetrakis(triphenylphosphine)palladium(0), [1,1'-bis(diphenylphosphino)ferrocene]palladium(II) dichloride, palladium on carbon, dichlorobis(triphenylphosphine)nickel(II), or bis(triphenylphosphine)palladium(II) dichloride), an alkali metal carbonate (representative examples include, but are not limited to, potassium carbonate, sodium carbonate, or cesium carbonate), or other alkali metal salts (sodium hydroxide, potassium hydroxide, sodium ethoxide, sodium methoxide, sodium tert-butoxide, potassium tert-butoxide, sodium hydride, sodium phosphate, potassium phosphate), and a suitable solvent, or in the absence of a solvent, to give a compound of formula VI-3. Preparation method II

[0167] Compound VI-1 can be prepared from compound VII-2. [ka]

[0168] In the Schemes, the symbols have the same meaning as defined above.

[0169] The compound of formula VII-1 can be reacted with a base (representative examples include, but are not limited to, pyrrolidine and piperidine) or an acid (representative examples include, but are not limited to, hydrochloric acid, acetic acid, trifluoroacetic acid) in the presence of a suitable solvent, or The reaction with the compound of formula VII-2 without a solvent can give the compound of formula VI-1.

[0170] The pharmaceutical compositions disclosed herein can be used in animals or humans.The compounds disclosed herein can be formulated as pharmaceutical compositions for oral, buccal, parenteral (e.g., intravenous, intramuscular or subcutaneous), topical, rectal or intranasal administration, or in a form suitable for administration by inhalation or insufflation.The compounds disclosed herein can also be formulated for sustained release according to methods well known to those skilled in the art.Examples of such formulations can be found in U.S. Pat. Nos. 3,119,742, 3,492,397, 3,538,214, 4,060,598 and 4,173,626.

[0171] The formulations may be conveniently presented in unit dosage form and may be prepared by any method known in the pharmaceutical industry. The amount of active ingredient that can be combined with carrier materials to produce a single dosage form varies depending on the animal being treated and the particular mode of administration. The amount of active ingredient that can be combined with carrier materials to produce a single dosage form will generally be the amount of compound that produces a therapeutic effect. Generally, out of 100%, this amount will range, for example, from about 0.1% to about 25% (e.g., 1%, 2%, 5%, 10%, 15%, 20%) of active ingredient.

[0172] Therapeutic compositions or formulations of the present invention suitable for oral administration may be in the form of capsules, cachets, pills, tablets, lozenges (with flavored bases, usually sucrose and acacia or tragacanth), powders, granules, or as a solution or suspension in an aqueous or non-aqueous liquid, or as an oil-in-water or water-in-oil liquid emulsion, or as an elixir or syrup, or as a lozenge (with an inert base, such as gelatin and glycerin, or sucrose and acacia), and / or mouthwash, each containing a predetermined amount of a compound of the present invention as the active ingredient. The compounds of the present invention may also be administered as a bolus, electuary, or paste.

[0173] In solid dosage forms of the invention for oral administration (capsules, tablets, pills, dragees, powders, granules, etc.), the alcohol or inhibitor according to the invention may be mixed with one or more pharma- ceutically acceptable carriers, such as sodium citrate or dicalcium phosphate, and / or any of the following: fillers or extenders, such as starch, lactose, sucrose, glucose, mannitol and / or silicic acid, binders, such as carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidone, sucrose and / or acacia, humectants, such as glycerol, agar-agar, calcium carbonate, dibasic saccharides, sorbitol ... Mix with disintegrating agents such as potato or tapioca starch, alginic acid, certain silicates, sodium carbonate and sodium starch glycolate, dissolution retarders such as paraffin, absorption promoters such as quaternary ammonium compounds, wetting agents such as cetyl alcohol, glycerol monostearate and polyethylene oxide-polypropylene oxide copolymers, absorbents such as kaolin and bentonite clay, lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate and mixtures thereof, and coloring agents. In the case of capsules, tablets and pills, the pharmaceutical composition may also contain buffering agents. Solid compositions of similar type may also be utilized as fillers in soft and hard-filled gelatin capsules, using excipients such as lactose or milk sugar, and high molecular weight polyethylene glycols, etc.

[0174] Liquid dosage forms for oral administration of the compounds of the present invention include pharma- ceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups, and elixirs. In addition to the active ingredient, the liquid dosage forms may contain, for example, water or other solvent, ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, propylene glycol esters ... The composition may include inert diluents commonly used in the art, such as solubilizing and emulsifying agents, such as ethylene glycol, 1,3-butylene glycol, oils (cottonseed, peanut, corn, germ, olive, castor and sesame oils, among others), glycerol, tetrahydrofuryl alcohol, polyethylene glycol and fatty acid esters of sorbitan, and mixtures thereof. Additionally, cyclodextrins, such as hydroxypropyl-β-cyclodextrin, may be used to solubilize the compounds.

[0175] In addition to inert diluents, oral compositions can also contain adjuvants such as wetting agents, emulsifying and suspending agents, sweetening agents, flavoring agents, coloring agents, perfumes and preservatives. In addition to the alcohol or inhibitor according to the invention, suspensions can contain suspending agents such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, and mixtures thereof.

[0176] Formulations of the pharmaceutical compositions of the present invention for rectal or vaginal administration can be prepared by mixing one or more alcohols or inhibitors of the present invention with one or more suitable non-irritating excipients or carriers, including, for example, cocoa butter, polyethylene glycol, suppository wax or salicylates, and can be presented as suppositories that are solid at room temperature but liquid at body temperature and thus melt in the rectum or vaginal cavity and release the active pharmaceutical agent of the present invention.Formulations of the present invention suitable for vaginal administration also include pessaries, tampons, creams, gels, pastes, foams or spray formulations containing such carriers known in the art to be suitable.

[0177] Dosage forms for topical or transdermal administration of an alcohol or other inhibitor according to the present invention include powders, sprays, ointments, pastes, creams, lotions, gels, solutions, patches and inhalants. The active compound may be mixed under sterile conditions with a pharma- ceutically acceptable excipient, carrier or diluent, including any preservatives, buffers or propellants which may be required.

[0178] For intranasal administration or administration by inhalation, the compounds disclosed herein can be conveniently delivered in the form of a solution or suspension from a pump-type spray container that is squeezed or pumped by the patient, or as an aerosol spray presentation from a pressurized container or nebulizer, with the use of a suitable propellant, such as dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In the case of a pressurized aerosol, the dosage unit can be determined by providing a valve to deliver a metered amount. The pressurized container or nebulizer can contain a solution or suspension of the compounds disclosed herein. Capsules and cartridges (e.g., made from gelatin) for use in an inhaler or insufflator can be formulated containing a powder mix of the compounds disclosed herein and a suitable powder base, such as lactose or starch.

[0179] Ointments, pastes, creams and gels may contain, in addition to the alcohol or other inhibitors of the present invention, excipients such as animal and vegetable fats, oils, waxes, paraffins, starches, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonite, silicic acid, talc and zinc oxide or combinations thereof.

[0180] Powders and sprays can contain, in addition to the compounds of the invention, excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates and polyamide powder, or mixtures of these substances. Sprays can additionally contain customary propellants, such as chlorofluorohydrocarbons and volatile unsubstituted hydrocarbons, such as butane and propane.

[0181] Ophthalmic formulations, eye ointments, powders, solutions and the like, are also contemplated as being within the scope of the present invention.

[0182] Pharmaceutical compositions of the invention suitable for parenteral administration comprise one or more alcohols or inhibitors according to the invention in combination with one or more pharma- ceutically acceptable sterile isotonic aqueous or non-aqueous solutions, dispersions, suspensions or emulsions, which may contain antioxidants, buffers, bacteriostats, solutes which render the formulation isotonic with the blood of the intended recipient, or dispersing or thickening agents, or sterile powders which can be reconstituted into sterile injectable solutions or dispersions immediately before use.

[0183] In some cases, it is desirable to delay the absorption of alcohol or inhibitor from subcutaneous or intramuscular injection in order to prolong the effect of alcohol or inhibitor according to the present invention.This can be achieved by using a liquid suspension of crystalline or amorphous material with poor water solubility.The rate of absorption of the drug then depends on its dissolution rate, which in turn can depend on crystal size and crystalline form.Alternatively, delayed absorption of parenterally administered compositions is achieved by dissolving or suspending alcohol or inhibitor in an oil vehicle.One strategy for depot injection includes the use of polyethylene oxide-polypropylene oxide copolymer, a vehicle that is fluid at room temperature and solidifies at body temperature.

[0184] The pharmaceutical compounds of the present invention may be administered alone or in combination with, simultaneously with, subsequently with, or sequentially with one or more active agents, other medicinal agents, or other agents commonly prescribed or used to treat the symptoms of obesity / overweight or its comorbidities, as well as with pharmacologic acceptable excipients, carriers, or diluents as described above.

[0185] The amount of pharmacological agent in the oral unit dosage form, as single or multiple doses, is the amount that is effective for treating neurological disorders.As recognized by those skilled in the art, the exact dose to be used will depend on various factors, such as the condition itself, the severity of the condition being treated, the specific composition used, and various physical factors of the individual being treated.In vitro or in vivo assays can be used as necessary to help identify the optimal dosage range.

[0186] The proposed dose of the compounds disclosed herein for oral, parenteral or buccal administration to an average adult human for the treatment or prevention of disease conditions herein is about 0.1 mg to about 2000 mg. In certain embodiments, the proposed dose is about 0.1 mg to about 200 mg (e.g., 1 mg, 5 mg, 10 mg, 20 mg, 50 mg, 75 mg, 100 mg, 150 mg) of active ingredient per unit dose. Regardless of the proposed dose, administration of the compounds can be performed, for example, 1, 2, 3, or 4 times per day, or 1, 2, 3, 4, or 5 times per week.

[0187] Aerosol formulations for the treatment or prevention of the conditions cited herein for an average adult human are preferably adjusted so that each metered dose or "puff" of aerosol contains about 20 μg to about 10,000 μg, preferably about 20 μg to about 1000 μg (e.g., 25 μg, 50 μg, 100 μg, 200 μg, 500 μg, 750 μg) of a compound disclosed herein. The total daily dose with aerosol will be in the range of about 100 μg to about 100 mg (e.g., 200 μg, 500 μg, 1 mg, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 75 mg). In certain embodiments, the total daily dose with aerosol will generally be in the range of about 100 μg to about 10 mg (e.g., 200 μg, 500 μg, 1 mg, 2 mg, 5 mg, 7.5 mg). Administration may be several times daily, for example 1, 2, 3, 4, 5 or 8 times, giving for example 1, 2 or 3 doses each time.

[0188] The compounds of the present invention can be prepared by synthetic methods known to those skilled in the art of organic synthesis, medicinal chemistry, and related fields. The compounds can be prepared using the methods described below, together with the methods or modifications thereto. The reactions are carried out in solvents appropriate to the reagents and materials used and suitable for the transformations being carried out. The starting materials of the examples contained herein are commercially available or easily prepared by standard methods from known materials. For example, the following reactions are illustrative and not limiting of the preparation of some of the starting materials and examples used herein. EXAMPLES

[0189] Example of synthesis method Scheme A for making compound 10-1 [ka] To a suspension of 5-chloroacetyloxindole 1 (820 mg, 4 mmol) in EtOH / THF (20 mL / 20 mL) was added thiobenzamide 2-2 (550 mg, 4 mmol). The mixture was heated at 80° C. for 16 h and then cooled. The solution was concentrated in vacuo to give an orange solid 8. MS m / z: 293.20 (M+H).

[0190] To this solid 8 was added EtOH / THF (20 mL / 20 mL) (or use the reaction mixture above), 5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid 4 (668 mg, 4 mmol) and piperidine (400 mL). The mixture was heated at 80° C. for 5 h. After cooling to room temperature, the reaction mixture was filtered and washed with EtOH (1 mL) to give an orange solid 9. 1 HNMR (300 MHz, DMSO-d6) d 13.80 (s, 1H), 12.40 (s, 1H), 11.10 (s,1H), 8.47 (s,1H), 8.07 - 8.12 (m, 3H), 7.94 (d, 1H, J =8.00Hz), 7.86 (s, 1H), 7.55 - 7.6 (m,3H), 7.01 (d, 1H, J = 8.10Hz),2.59 (s, 3H), 2.57 (s, 3H);MS m / z: 442.20 (M+H).

[0191] To a solution of 9 (34 mg, 0.077 mmol) in DMF (1.5 mL) was added HATU (35 mg, 0.092 mmol), diisopropylethylamine (30 mL, 0.168 mmol) and 1-methylpiperazine 6-1 (15 mL, 0.13 mmol). The mixture was stirred at room temperature for 16 h and then concentrated in vacuo. The residue was added with CH2Cl2 (2 mL) and extracted with H2O (3 x 1.5 mL). The organic layer was dried over Na2SO4 and concentrated in vacuo. The residue was purified by column chromatography (CH2Cl2 / MeOH / Et3N) to give a yellow solid 10-1. 1 HNMR (300 MHz, DMSO-d6) d 13.68 (s, 1H), 11.10 (s, 1H), 8.44 (s,1H), 8.07 - 8.10(m, 3H), 7.91 (d, 1H, J =8.00Hz), 7.80 (s, 1H), 7.68 - 7.76 (m, 2H), 7.52 -7.58(m, 1H), 7.01 (d, 1H, J = MS m / z:524.20(M+H). Scheme B for making compound 7-1 [ka]

[0192] To a suspension of 5-chloroacetyloxyindole 1 (42 mg, 0.2 mmol) in EtOH / THF (2 mL / 1 mL) was added thioacetamide 2-1 (15 mg, 0.2 mmol). The mixture was heated at 80° C. for 16 h and then cooled. The solution was concentrated in vacuo to give an orange solid 3. 1HNMR (300 MHz, DMSO-d6) δ 10.50 (br. S, 1H), 7.72 - 7.80 (m, 2H), 7.33 (s, 1H),7.16 (s, 1H), 6.86 (d,1H, J = 8.63 Hz), 3.42 - 4.54 (m, 2H); MS m / z231.10(M+H).

[0193] To a solution of 3 (53 mg, 0.2 mmol) in EtOH / THF (2 mL / 1 mL) (or using a solution of the reaction mixture above in EtOH / THF (2 mL / 1 mL)), 5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid 4 (33.4 mg, 0.2 mmol) and piperidine (21.8 μL) were added. The mixture was heated at 80° C. for 2 h. After cooling to room temperature, the reaction mixture was filtered and washed with EtOH (1 mL) to give a reddish solid 5. 1 HNMR (300 MHz, DMSO-d6) δ 13.80 (s, 1H), 12.10 (br.s, 1H),11.08 (s, 1H), 8.35(s, 1H), 7.85 (s, 1H), 7.78 -7.81 (m, 2H), 6.94 (d, 1H, J = 8.11Hz), 2.74 (s, 3H), 2.56 (s, 3H), 2.52(s, 3H); MS m / z 380.21 (M+H).

[0194] To a solution of 5 (20 mg, 0.052 mmol) in DMF (1.5 mL) was added HATU (24 mg, 0.063 mmol), diisopropylethylamine (30 μL, 0.168 mmol) and 1-methylpiperazine 6-1 (10 μL, 0.090 mmol). The mixture was stirred at room temperature for 16 h and then concentrated in vacuo. The residue was added to CHCl (2 mL) and extracted with H0 (3 × 1.5 mL). The organic layer was dried over NaSO and concentrated in vacuo. The residue was purified by column chromatography (CHCl / MeOH / EtN ) to give a yellow solid 7-1. 1 H NMR (300 MHz, DMSO-d6) δ 11.00 (s, 1H), 8.30 (s, 1H),7.83 (s, 1H), 7.65 - 7.78 (m, 2H), 6.94 (d, 1H, J =8.18Hz),3.02 - 3.20 (m, 4H), 2.74 (s, 3H), 2.5 - 2.58 (m, 4H), 2.5 (s, 6H), 2.3 (s,3H); MS m / z 462.20(M+H). Scheme C for making compound 14-3 [ka]

[0195] To a solution of 9 (1.55 g, 3.5 mmol) in DMF (130 mL) was added HATU (1.6 g, 4.2 mmol), diisopropylethylamine (1.6 mL, 9.2 mmol) and N,N-diethyl-1,2-ethanediamine 6-2 (0.6 mL, 4.2 mmol). The mixture was stirred at room temperature for 16 h and concentrated in vacuo. The residue was added to CHCl (800 mL) and extracted with HO (200 mL), saturated NaHCO (200 mL), HO (2×200 mL) and brine (200 mL). The organic layer was dried over NaSO and concentrated in vacuo. The residue was added to a small amount of MeOH and filtered to give a yellow solid 14-3. 1 HNMR (300 MHz, DMSO-d6) δ 13.70 (s, 1H), 11.10 (s, 1H),8.44 (s, 1H), 8.07 - 8.10 (m, 3H), 7.92 (d, 1H, J =8.10Hz), 7.81 (s, 1H), 7.3 - 7.6 (m, 3H), 7.00(d, 1H, J =8.10Hz), 3.2 -3.3 (m, 2H), 2.5 - 2.6 (m, 6H), 2.51 (s, 3H), 2.48(s, 3H), 1.00(t, 6H, J=6.90 Hz); MS m / z 540.20 (M+H). Scheme D for making compound 15-1 [ka]

[0196] To a suspension of 5-chloroacetyloxyindole 1 (42 mg, 0.2 mmol) in EtOH / THF (1 mL / 1 mL) was added thionicotinamide 2-3 (27.8 mg, 0.2 mmol). The mixture was heated at 80° C. for 16 h and then cooled. The solution was concentrated in vacuo to give an orange solid 11. MS m / z: 294.20 (M+H).

[0197] To this solid 11 was added EtOH / THF (1 mL / 1 mL), 5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (33.4 mg, 0.2 mmol) and piperidine (21.8 μL). The mixture was heated at 80° C. for 2 h. After cooling to room temperature, the reaction mixture was concentrated and filtered to give an orange solid 12. MS m / z: 443.20 (M+H).

[0198] To a solution of solid 12 (44 mg, 0.10 mmol) in DMF (1.5 mL) was added HATU (35 mg, 0.12 mmol), diisopropylethylamine (50 μL, 0.33 mmol) and 1-methylpiperazine 6-1 (30 μL, 0.26 mmol). The mixture was stirred at room temperature for 16 h and then concentrated in vacuo. The residue was added with CH2Cl2 (2 mL) and extracted with H2O (1.5 mL). The organic layer was dried over Na2SO4 and concentrated in vacuo. The residue was purified by column chromatography (CH2Cl2 / MeOH / Et3N) to give yellow solid 15-1. 1 HNMR (400 MHz, DMSO-d6 ) δ 13.55 (s, 1H), 11.00 (s, 1H),9.20 (d, 1H, J = 1.60 Hz), 8.64 (dd, 1H, J =4.70, 1.60 Hz), 8.35- 8.37 (m, 2H), 8.10 (s, 1H), 7.84 (dd, 1H, J = 8.00, 1.60Hz), 7.71 (s,1H), 7.52 (ddd, J = 8.00, 4.70, 0.70 Hz, 1H), 6.92 (d, 1H, J =8.00Hz), 3.07 - 3.2 (m, 4H), 2.26 (s, 3H), 2.24 (s,3H), 2.24 - 2.3 (m, 4H), 2.13(s, 3H);MS m / z:525.20(M+H). Scheme E for preparing compound 15-3 [ka]

[0199] To a solution of solid 12 (44 mg, 0.10 mmol) in DMF (1.5 mL) was added HATU (35 mg, 0.12 mmol), diisopropylethylamine (50 mL, 0.33 mmol) and N,N-diethyl-1,2-ethanediamine 6-2 (23 mL, 0.2 mmol). The mixture was stirred at room temperature for 16 h and then concentrated in vacuo. The residue was added with CH2Cl2 (2 mL) and extracted with H2O (1.5 mL). The organic layer was dried over Na2SO4 and concentrated in vacuo. The residue was purified by column chromatography (CH2Cl2 / MeOH / Et3N) to give a yellow solid 15-3. 1 HNMR (400 MHz, DMSO-d6) d 13.60 (s, 1H), 11.00 (s, 1H), 9.18 (d,1H, J = 1.60Hz),8.64 (dd, 1H, J = 4.80, 1.60 Hz), 8.33 - 8.37(m, 2H), 8.09 (s, 1H), 7.83 (dd,1H, J = 8.00, 2.4 -2.6 (m, 4H), 0.90 (t,J = 7.10 Hz, 6H); MS m / z:525.20(M+H). MS m / z:541.20(M+H).

[0200] - Compound 15-3 can be prepared from compound 12 and N,N-diethyl-1,2-ethanediamine 6-2 using a method similar to that used to prepare compound 15-1.

[0201] Biomedical Assays

[0202] Example 1: Compound 14-3 reduces body weight in obese mice without suppressing daily caloric or water intake

[0203] To evaluate the in vivo efficacy of compound 14-3, a preferred embodiment of the compound of the present invention, in treating and ameliorating obesity and related diseases such as metabolic syndrome, a modified high-fat diet (HFD) previously used was used to induce obesity and severe fatty liver disease in mice (Derdak et al., J of Hepatology 2013;58(4):785-91).

[0204] Five-week-old male C57Bl / 6J mice (12-18 / group, Jackson Laboratory, Bar Harbor, ME) were fed ad libitum with a modified high-fat diet or a control diet (Bioserv, Frenchtown, NJ) for 15 weeks. The caloric profile of the modified HFD (60% of calories from fat) was similar to the composition of a previously published diet that effectively induced obesity, adiposity, and insulin resistance in this mouse strain (Cong et al., Life Sci, 2008;82:983-990). We verified the efficacy of this diet to induce obesity in various pilot studies. At the end of the 15-week feeding regimen, the diet caused a significant weight gain in these mice.

[0205] After 15 weeks on the modified HFD, mice were placed on a compound 14-3 (or control vehicle) dosing regimen, receiving an induction dose of 5 mg / kg (orally, 3 times per week for the first 3 weeks) followed by a therapeutic dose of 10 mg / kg (orally, 3 times per week for an additional 5 weeks). Animals were monitored daily for changes in body weight, food / water intake, and adverse effects over the course of drug treatment.

[0206] As shown in Figure 1A, compound 14-3 treatment not only prevented further weight gain in mice on HFD, but also induced a gradual weight loss. As Figure 1B demonstrates, at the time of euthanasia, there was a significant (about 20%) weight difference between HFD-fed mice treated with compound 14-3 and those treated with control vehicle. Furthermore, compound 14-3-induced weight loss in HFD-fed mice was not associated with a decrease in food intake (Figure 1C) or water intake (Figure 1D), indicating that pharmaceutical compositions containing the compounds of the present invention should be very safe, with no detectable side effects other than the transient, self-limited mild diarrhea seen in two mice at the beginning of drug treatment. No changes in behavior or activity were observed in the mice.

[0207] Example 2: Compound 14-3 treatment does not affect intestinal fat absorption, molecular mediators of appetite, or energy expenditure in brown adipose tissue

[0208] The significantly lower body weights of compound-treated, HFD-fed mice compared to vehicle-treated, HFD-fed controls prompted further investigation.

[0209] Referring to FIG. 2A, a standard biochemistry kit (Biovision, Mountain View, CA) was used. Fecal triglyceride content was assessed using a ELISA kit (View, CA). Stool samples were collected over 3 days at the 5th week of treatment. Fecal triglyceride content was normalized to stool mass. Although HFD naturally increases fecal triglyceride abundance, as shown here, there is little difference between vehicle-treated and compound 14-3-treated mice, indicating that the compounds of the present invention do not alter intestinal fat absorption. Therefore, this mechanism cannot explain the significant weight loss observed in drug-treated mice.

[0210] Now referring to FIG. 2B, hypothalamic molecular mediators of hunger and satiety signaling in the hypothalamus were analyzed using quantitative real-time PCR with commercially available probes (Thermo Fisher Scientific Inc., Waltham, MA). AgRP and NPY are satiety-inducing signals, whereas POMC is a potent satiety-inducing signal in the hypothalamus. There was no significant difference in the expression of appetite-inducing genes between vehicle-treated and compound 14-3-treated animals fed HFD. This was consistent with the food intake information we collected during the course of the experiment. Furthermore, there was a significant decrease in the expression of satiety-inducing POMC in HFD-fed compound 14-3-treated mice compared to their corresponding control groups. Thus, the expression levels of hypothalamic hunger or satiety genes could explain the significant weight loss in HFD-fed compound 14-3-treated mice. It was concluded that the decreased satiety occurred after a prolonged period of negative energy balance in this group.

[0211] Finally, brown adipose tissue (BAT) recruitment was investigated. BAT is a well-known site for dissipating excess energy to prevent weight gain by inducing thermogenesis. Importantly, the expression levels of the two investigated markers of thermogenic BAT activation - UCP1 and DIO2 - did not differ in the two HFD-fed groups as measured by quantitative real-time PCR (Figure 2C), indicating similar levels of BAT activation in response to HFD. These findings led us to conclude that other mechanisms are likely responsible for the weight loss observed in compound 14-3-treated HFD-fed mice.

[0212] Example 3: Compound 14-3 treatment induces favorable changes in body composition

[0213] Consistent with the effects of compound 14-3 seen in the above examples, favorable changes in body composition of compound 14-3 treated HFD fed mice were also observed through macroscopic examination at the time of euthanasia.

[0214] Most importantly, compound 14-3 significantly reduced epididymal fat pad weight and epididymal fat / body weight ratio (Figures 3A and 3B) as well as unilateral fat pad weight and inguinal fat / body weight ratio (Figures 3C and 3D). The former anatomical site corresponds to visceral fat depos, while the latter belongs to subcutaneous fat depos from the perspective of human health. Both of these changes were considered to be very substantial and beneficial in the anti-obesity effect profile of the compounds of the present invention.

[0215] Example 4: Compound 14-3 treatment induces favorable changes in eWAT adipocyte morphology and TGF-β gene expression

[0216] Further insight into the morphological changes in eWAT assessed by H&E staining of eWAT revealed that the reduction in adipocyte size in compound 14-3-treated HFD-fed mice (Figure 4A) was due to a reduction in the overall fat content in these cells (Figure 4B).

[0217] Since obesity is associated with low-grade inflammation in adipose tissue, we therefore observed increased TGF-β expression in the epididymal fat pads of HFD-fed mice.More importantly, treatment with compound 14-3 reduced the abundance of TGF-β in eWAT, indicating that compound 14-3 has anti-inflammatory properties (Figure 4C).

[0218] Example 5: Compound 14-3 treatment induces favorable changes in iWAT adipocyte morphology

[0219] A similar pattern of morphological changes was observed by analysis of inguinal (subcutaneous) white adipose tissue (iWAT) assessed by H&E staining followed by morphometry: the reduction in adipocyte size in the compound 14-3-treated HFD-fed group (Figure 5A) was due to a reduction in overall fat content in iWAT adipocytes (Figure 5B).

[0220] Example 6: Compound 14-3 treatment induces favorable changes in gene expression in eWAT

[0221] To gain more detailed insight into the metabolic changes induced by compound 14-3 treatment in visceral adipose tissue (eWAT), the expression of genes involved in lipid transport and degradation, β-oxidation, de novo lipogenesis and insulin sensitivity was examined.

[0222] As Figure 6 demonstrates, compound 14-3 treatment induced catabolic events in visceral white adipocytes. For example, expression of RAR-related orphan receptor alpha (RORA, Figure 6A), a nuclear receptor with anti-adipose and anti-inflammatory properties, is significantly increased in eWAT of HFD-fed compound-14-3-treated mice. Acyl-coenzyme A dehydrogenase, C-4 to C-12 linear chain (ACADM, Figure 6B) is known to be important in the breakdown of medium-chain fatty acids. Increased gene expression of ACADM was seen in the compound 14-3-treated group, suggesting that compound 14-3 has catabolic properties.

[0223] Furthermore, we found that the expression of peroxisomal acyl-coenzyme A oxidase 1 (ACOX1, Figure 6C) was increased by compound 14-3 treatment, shedding light on the "fat burning" properties of the compounds of the present invention. Similarly, malonyl-CoA decarboxylase (MLYCD, Figure 6D) was induced by compound 14-3 treatment. This event is associated with the reduction of malonyl-CoA synthesis and the inhibition of de novo lipogenesis by compound 14-3. Finally, gene expression of phosphoenolpyruvate carboxykinase (PEPCK, Figure 6E) in eWAT of HFD-fed compound 14-3-treated mice was comparable to that of control-fed mice, suggesting that compound 14-3 may have a role in preventing insulin resistance.

[0224] Example 7: Compound 14-3 treatment increases expression of mediators of fatty acid oxidation and ameliorates leptin resistance in HFD-fed mice

[0225] Many of the beneficial metabolic effects are associated with FGF21, which itself can further enhance fatty acid oxidation (Xu J et al., Diabetes (2009) 58 (1): 250-259; Li H et al., Diabetes (2012) 61 (4): 797-806). Therefore, we also measured serum levels of FGF21 using a commercially available ELISA kit. As shown in Figure 7A, treatment of HFD-fed mice with Compound-14-3 increased serum FGF21 levels and gene expression (Figure 7B). These data suggest that FGF21 activity appeared to be specifically induced by Compound-14-3 treatment. Thus, in one embodiment of the present invention, Compound-14-3 treatment is used to increase fatty acid oxidation, resulting in a reduction in fat content in iWAT and eWAT and a reduction in subject body weight.

[0226] Crosstalk between leptin and FGF21 has been proposed in relation to the anti-obesity effects of FGF21, and because the inhibitory effect of exogenous FGF21 on circulating leptin levels has been previously observed in non-human primates, we also measured serum leptin levels using a commercially available ELISA kit. As expected, the change in fat content in the HFD group treated with compound 14-3 was followed by a decrease in serum levels of the fat-derived "satiety" hormone leptin, indicating the improvement in leptin resistance resulting from treatment with the compound of the present invention (Figure 7C). Thus, the lower circulating levels of leptin were most likely due to a drug-induced decrease in the mass of fat storage tissue. This finding could explain the decrease in POMC gene expression in the hypothalamus, since leptin can directly regulate the hypothalamic melanocortin system by altering the activity of POMC neurons.

[0227] Example 8: Compound 14-3 treatment induces favorable changes in body composition, including in the liver

[0228] Favorable changes in body composition were also observed in the liver (Figures 8A and 8B): HFD feeding in vehicle-treated mice promoted hepatomegaly due to ectopic fat accumulation in this organ. The enlarged liver appeared pale yellow, consistent with steatosis. On the other hand, compound 14-3 did not significantly alter the HFD-fed liver. It significantly reduced the size of the mice's livers and helped them maintain a healthier, darker brown appearance (Figure 8A, right). The beneficial effects on liver size and appearance were consistent as part of the overall improvement in metabolic profile following compound 14-3 treatment.

[0229] Example 9: Changes in body composition induced by compound 14-3 were associated with better glucose tolerance and whole-body insulin sensitivity

[0230] Bearing in mind that a good anti-obesity drug should not only have clinically significant weight loss results (>5%) but also delay or prevent the onset of type II diabetes, we evaluated the antidiabetic properties of compound 14-3.

[0231] The described beneficial changes in body composition improved all aspects of the metabolic syndrome, including the underlying insulin resistance. Therefore, to fully characterize this animal model, we also assessed insulin signaling in live animals at 5 weeks of compound 14-3 treatment by performing an oral glucose tolerance test (OGTT, Figures 9A-C) and an intraperitoneal insulin tolerance test (ITT, Figures 9D-E).

[0232] To exclude the effect of the last meal on blood glucose levels, both OGTT and ITT studies were performed on mice that had fasted for 6 hours before the procedure. In both studies, we measured fasting glucose levels 30 minutes before the start of the assay to define baseline conditions. In the OGTT assay, mice were gavaged with 2 g / kg glucose dissolved in water. After administration of glucose, blood glucose levels were measured using a commercial glucometer by nicking the tail vein. The resulting data were plotted against time (Figure 9A) and area under the curve (AETC) calculations were performed (Figure 9B). Furthermore, blood glucose levels measured at 120 minutes after gavage were used to describe the overall glucose tolerance of the mice (Figure 9C). The data suggest that compound 14-3 treatment significantly improved glucose tolerance in HFD-fed mice, as evidenced by a smaller AUC and reduced 120-minute glucose levels when compared to vehicle-treated littermates.

[0233] In the ITT study, we administered 0.75 g / kg human recombinant insulin (Humulin N, Eli Lilly, Cambridge, MA) intraperitoneally at the beginning of the assay, and blood glucose was measured for 120 min as well. The steeper drop in blood glucose levels in response to insulin and the smaller AUC in the ITT study indicated that mice treated with compound 14-3 were more sensitive to the effects of insulin than their HFD-fed and vehicle-treated littermates. Taken together, these data indicate that compound 14-3 can not only promote weight loss in HFD-fed mice, but also improve overall glucose homeostasis and insulin sensitivity. Improved insulin resistance and better glucose tolerance are highly desirable clinical effects in the treatment of obesity, type II diabetes, metabolic syndrome, and NAFLD.

[0234] Example 10: Compounds of the invention prevent excess triglyceride accumulation in human hepatocytes

[0235] To determine whether preferred embodiments of the compounds of the present invention can be used to treat and ameliorate obesity and related diseases such as non-alcoholic fatty liver disease (NAFLD), preferred embodiments of the compounds of the present invention were evaluated herein for their ability to inhibit fat accumulation in cell culture.

[0236] First, a series of in vitro experiments were carried out using various human hepatocyte cultures. Human HepG2 hepatocytes were incubated with 1.6 mM palmitoleic acid in EMEM medium in the presence of .1 μM compound 14-3 or control vehicle, DMSO, for 48 h. After 48 h, cells were harvested and intracellular triglyceride content was measured by a biochemistry kit (Biovision, Mountain View, CA) as described in Derdak et al., J Hepatol. 2013;58(4):785-91. As shown in the figure (Figure 10A), palmitoleic acid treatment substantially increased the intracellular triglyceride content of HepG2 cells, but this event was significantly suppressed by compound 14-3, indicating a strong inhibitory effect on fat accumulation in human hepatocytes.

[0237] The effects of Compound 13-3-1, Compound 13-3-2, Compound 13-3-3, Compound 13-3-5, Compound 13-3-6, Compound 13-3-7, Compound 15-1, Compound 13-3-10 and Compound 13-3-11 as exemplary compounds of the present invention were tested. Human HepG2 hepatocytes were incubated with 0.8 mM palmitoleic acid in EMEM medium in the presence of 0.1 μM of the compounds or control vehicle, DMSO, for 24 hours. Subsequently, the cells were washed with PBS and the intracellular fat content was measured by AdipoRed / Hoechst 33258 double staining, which was evaluated by fluorescence measurement. As shown in the figure (Figure 10B), palmitoleic acid treatment substantially increased the intracellular triglyceride content of HepG2 cells, but this event was significantly suppressed by each of these nine compounds, respectively, showing comparable or greater inhibitory effects on fat accumulation in human hepatocytes compared to Compound 14-3.

[0238] The effects of compound 001, compound 004, compound 006, compound 013, compound 132, compound 133 and compound 134 were also tested as further exemplary compounds of the present invention. Human HepG2 hepatocytes were incubated with 0.8 mM palmitoleic acid in EMEM medium in the presence of 0.1 μM of the compounds of the present invention or control vehicle, DMSO, for 48 hours. Subsequently, the cells were washed with PBS and the intracellular fat content was measured by AdipoRed / Hoechst 33258 double staining, which was evaluated by fluorescence measurement. As shown in the figure (Figure 10C), palmitoleic acid treatment substantially increased the intracellular triglyceride content of HepG2 cells, but this event was significantly suppressed by each of these seven deuterated derivatives, which showed comparable or even greater inhibitory effects on fat accumulation in human hepatocytes compared to compound 14-3.

[0239] This observation led to the hypothesis that the compounds of the present invention may have a unique hepatotropic effect.By directly affecting hepatic fatty acid metabolism, the compounds of the present invention may reduce hepatic steatosis and subsequent liver damage in mouse models of NAFLD.

[0240] In conclusion, the compounds of the present invention, in a representative embodiment as compound 14-3, are attractive novel agents in the treatment and prevention of obesity or overweight, as well as the closely related type II diabetes and metabolic syndrome. The compounds of the present invention show a well-tolerated and highly effective weight loss profile. Specifically, the compounds of the present invention have demonstrated the ability to promote fatty acid oxidation and inhibit de novo fatty acid synthesis in an in vivo mouse model. Data showed improved insulin sensitivity, reduced inflammation, as well as reduced fatty acid deposition following treatment in a mouse model of diet-induced obesity. With respect to the liver, the compounds of the present invention improved many aspects of NAFLD, inhibited liver injury, and reduced liver triglyceride content in both an in vivo mouse model and in human hepatocyte cultures. Furthermore, treatment with the compounds of the present invention does not appear to affect caloric or water intake, induce satiety, or suppress hunger, making it attractive to patients who do not want some or all of the lifestyle restrictions often associated with dietary therapy or weight loss drugs. The compounds of the present invention act primarily on white adipose tissue (WAT) and the liver, ultimately resulting in weight loss. Thus, the compounds of the present invention are effective in treating obesity and related complications. These individuals may be ideal candidates for the treatment of existing diseases. Equivalent

[0241] The representative examples are intended to aid in the description of the invention and are not intended to limit the scope of the invention and should not be construed as such. Indeed, various modifications of the invention, and many further embodiments thereof, in addition to those shown and described herein, will become apparent to those skilled in the art from the entire contents of this document, which is meant to include examples and references to the scientific and patent literature. The examples contain important additional information, exemplification and guidance that are applicable to the practice of this invention in its various embodiments and equivalents thereof.

[0242] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art. Although any methods and materials similar or equivalent to those described herein can also be used in the practice or testing of this disclosure, the preferred methods and materials are described herein. The methods recited herein may be carried out in any order that is logically possible in addition to the specific order disclosed. Incorporation by Reference

[0243] References and citations to other documents, such as patents, patent applications, patent publications, journals, books, literature, web content, etc., have been made in this disclosure. All such documents are incorporated herein by reference in their entirety for all purposes to the maximum extent permitted by law. Although referred to as being incorporated by reference herein, any material or portion thereof that conflicts with existing definitions, references, or other disclosed material that is clearly described herein is incorporated only to the extent that no conflict occurs between the incorporated material and the disclosed material. In case of conflict, the conflict should be resolved in favor of this disclosure as the preferred disclosure. The present invention provides, for example, the following items. (Item 1) A method for treating a condition selected from the group consisting of obesity, overweight, type II diabetes and metabolic syndrome in a mammal, including a human, comprising administering to a mammalian subject in need thereof: (a) [ka] [ka] [ka] or an enantiomer, diastereomer, tautomer, or pharma- ceutically acceptable salt, solvate, ester, or prodrug thereof, which is effective in the treatment or prevention of a condition selected from the group consisting of obesity, overweight, type II diabetes, and metabolic syndrome in a mammal, including a human; and (b) administering a pharma- ceutically acceptable excipient, carrier, or diluent. A method for treating a condition selected from the group consisting of obesity, overweight, type II diabetes and metabolic syndrome in a mammal, including a human, comprising administering to a mammalian subject in need thereof: (a) A compound of formula I: [ka] or an enantiomer, diastereomer, tautomer, or a pharma- ceutically acceptable salt, solvate, ester, or prodrug thereof, selected from the group consisting of obesity, overweight, type II diabetes, and metabolic syndrome in mammals, including humans. 1. A pharmaceutical composition comprising a therapeutically effective amount of a compound of formula I, or an enantiomer, diastereomer, tautomer, or a pharma- ceutically acceptable salt, solvate, ester, or prodrug thereof, which is effective in the treatment or prevention of a condition, wherein the symbols have the following meanings, independently selected for each occurrence: R1 is hydrogen, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, aryl or substituted aryl, OR a , S.R. a , S(=O)2R e , S(=O)2OR e, C(=O)OR d , C(=O)R a or C(=O)NR b R c and R2 is a heterocycle or substituted heterocycle, aryl or substituted aryl; R3 is hydrogen, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, heterocycle or substituted heterocycle, aryl or substituted aryl; R4, R7, and R8 are each independently hydrogen, halogen, cyano, nitro, CF3, OCF3, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, aryl or substituted aryl, OR a , S.R. a , S(=O)R e , S(=O)2R e , P(=O)2R e , S(=O)2OR e , P(=O)2OR e , N.R. b R c , N.R. b S(=O)2R e , N.R. b P(=O)2R e , S(=O)2NR b R c , P(=O)2NR b R c , C(=O)OR e , C(=O)R a , C(=O)NR b R c ,OC(=O)R a ,OC(=O)NR b R c , N.R. b C(=O)OR e , N.R. d C(=O)NR b R c , N.R. d S(=O)2NR b R c , N.R. d P(=O)NR bR c , N.R. b C(=O)R a or NR b P(=O)2R e and R5 is alkyl or substituted alkyl, heterocycle or substituted heterocycle, aryl or substituted aryl, amino or substituted amino; R6 is hydrogen, halogen, cyano, nitro, CF3, OCF3, alkyl or substituted alkyl, heterocycle or substituted heterocycle, aryl or substituted aryl, or OR; a and R a is hydrogen, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, or aryl or substituted aryl; R b , R c and R d are independently hydrogen, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, heterocycle or substituted heterocycle, or aryl or substituted aryl, or optionally, b and R c together with the N to which they are attached form a heterocyclic ring or a substituted heterocyclic ring, R e is alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, or aryl or substituted aryl, And (b) a pharma- ceutically acceptable excipient, carrier, or diluent; The method of claim 1, further comprising administering (Item 3) A method for treating a condition selected from the group consisting of obesity, overweight, type II diabetes and metabolic syndrome in a mammal, including a human, comprising administering to a mammalian subject in need thereof: (a) A compound of formula II: [ka] or an enantiomer, diastereomer, tautomer, or a pharma- ceutically acceptable salt, solvate, ester, or prodrug thereof, which is effective in the treatment or prevention of a condition selected from the group consisting of obesity, overweight, type II diabetes, and metabolic syndrome in a mammal, including a human, comprising a compound of formula II, or an enantiomer, diastereomer, tautomer, or a pharma- ceutically acceptable salt, solvate, ester, or prodrug thereof, wherein the symbols have the following meanings, independently selected for each occurrence: Het is a 5- or 6-membered aromatic ring containing at least one heteroatom selected from N, O and S; R1 is hydrogen, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, aryl or substituted aryl, OR a , S.R. a , S(=O)2R e , S(=O)2OR e , C(=O)OR d , C(=O)R a or C(=O)NR b R c and R3 and R 10 are each independently hydrogen, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, heterocycle or substituted heterocycle, aryl or substituted aryl; R4, R7, and R8 are each independently hydrogen, halogen, cyano, nitro, CF3, OCF3, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, aryl or substituted aryl, OR a , S.R. a , S(=O)R e , S(=O)2R e , P(=O)2R e , S(=O)2OR e , P(=O)2OR e , N.R. b R c , N.R. b S(=O)2R e , N.R. b P(=O)2R e , S(=O)2NR b R c , P(=O)2NR b R c , C(=O)OR e , C(=O)R a , C(=O)NR b R c ,OC(=O)R a ,OC(=O)NR b R c , N.R. b C(=O)OR e , N.R. d C(=O)NR b R c , N.R. d S(=O)2NR b R c , N.R. d P(=O)NR b R c , N.R. b C(=O)R a or NR b P(=O)2R e and R5 is alkyl or substituted alkyl, heterocycle or substituted heterocycle, aryl or substituted aryl, amino or substituted amino; R6 and R9 are each independently hydrogen, halogen, cyano, nitro, CF3, OCF3, alkyl or substituted alkyl, heterocycle or substituted heterocycle, aryl or substituted aryl, or OR. a and R 14 and R 15 are independently hydrogen, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, heterocycle or substituted heterocycle, or aryl or substituted aryl, or optionally, 14 and R 15 together with the N to which they are attached form a heterocyclic ring or a substituted heterocyclic ring, R a represents hydrogen, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, or aryl or substituted aryl; R b , R c and R d are independently hydrogen, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, heterocycle or substituted heterocycle, or aryl or substituted aryl, or optionally, b and R c together with the N to which they are attached form a heterocyclic ring or a substituted heterocyclic ring, R e is alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, or aryl or substituted aryl, And (b) a pharma- ceutically acceptable excipient, carrier, or diluent; The method of claim 1, further comprising administering (Item 4) A method for treating a condition selected from the group consisting of obesity, overweight, type II diabetes and metabolic syndrome in a mammal, including a human, comprising administering to a mammalian subject in need thereof: (a) A compound of formula III: [ka] or a pharmaceutical composition comprising an enantiomer, diastereomer, tautomer, or pharma- ceutically acceptable salt, solvate, ester, or prodrug thereof, effective in the treatment or prevention of a condition selected from the group consisting of obesity, overweight, type II diabetes, and metabolic syndrome in a mammal, including a human, comprising: wherein the symbols have the following meanings, independently selected for each occurrence: Het is a 5- or 6-membered aromatic ring containing at least one heteroatom selected from N, O and S; R1 is hydrogen, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, aryl or substituted aryl, OR a , S.R. a , S(=O)2R e , S(=O)2OR e , C(=O)OR d , C(=O)R a or C(=O)NR b R c and R3 and R 10 are each independently hydrogen, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, heterocycle or substituted heterocycle, aryl or substituted aryl; R4, R7, and R8 are each independently hydrogen, halogen, cyano, nitro, CF3, OCF3, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, aryl or substituted aryl, OR a , S.R. a , S(=O)R e , S(=O)2R e , P(=O)2R e , S(=O) 2OR e , P(=O)2OR e , N.R. b R c , N.R. b S(=O)2R e , N.R. b P(=O)2R e , S(=O)2NR b R c , P(=O)2NR b R c , C(=O)OR e , C(=O)R a , C(=O)NR b R c ,OC(=O)R a ,OC(=O)NR b R c , N.R. b C(=O)OR e , N.R. d C(=O)NR b R c , N.R. d S(=O)2NR b R c , N.R. d P(=O)NR b R c , N.R. b C(=O)R a or NR b P(=O)2R e and R5 is alkyl or substituted alkyl, heterocycle or substituted heterocycle, aryl or substituted aryl, amino or substituted amino; R6 and R9 are each independently hydrogen, halogen, cyano, nitro, CF3, OCF3, alkyl or substituted alkyl, heterocycle or substituted heterocycle, aryl or substituted aryl, or OR. a and R 11 is hydrogen or C 1~4 is alkyl, R 12 and R 13 are independently hydrogen, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, heterocycle or substituted heterocycle, or aryl or substituted aryl, or optionally, 12 and R 13 together with the N to which they are attached form a heterocyclic ring or a substituted heterocyclic ring, n is an integer selected from 2, 3, 4, 5, and 6; R a is hydrogen, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, or aryl or substituted aryl; R b , R c and R d are independently hydrogen, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, heterocycle or substituted heterocycle, or aryl or substituted aryl, or optionally, b and R c together with the N to which they are attached form a heterocyclic ring or a substituted heterocyclic ring, R e is alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, or aryl or substituted aryl, And (b) a pharma- ceutically acceptable excipient, carrier, or diluent; The method of claim 1, further comprising administering (Item 5) A method for treating a condition selected from the group consisting of obesity, overweight, type II diabetes and metabolic syndrome in a mammal, including a human, comprising administering to a mammalian subject in need thereof: (a) A compound of formula IV: [ka] or an enantiomer, diastereomer, tautomer, or a pharma- ceutically acceptable salt, solvate, ester, or prodrug thereof, which is effective in the treatment or prevention of a condition selected from the group consisting of obesity, overweight, type II diabetes, and metabolic syndrome in a mammal, including a human, comprising a compound of formula IV, or an enantiomer, diastereomer, tautomer, or a pharma- ceutically acceptable salt, solvate, ester, or prodrug thereof, wherein the symbols have the following meanings, independently selected for each occurrence: Het is a 5- or 6-membered aromatic ring containing at least one heteroatom selected from N, O and S; R1 is hydrogen, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, aryl or substituted aryl, OR a , S.R. a , S(=O)2R e , S(=O)2OR e , C(=O)OR d , C(=O)R a or C(=O)NR b R c and R3 and R 10are each independently hydrogen, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, heterocycle or substituted heterocycle, aryl or substituted aryl; R4, R7, and R8 are each independently hydrogen, halogen, cyano, nitro, CF3, OCF3, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, aryl or substituted aryl, OR a , S.R. a , S(=O)R e , S(=O)2R e , P(=O)2R e , S(=O)2OR e , P(=O)2OR e , N.R. b R c , N.R. b S(=O)2R e , N.R. b P(=O)2R e , S(=O)2NR b R c , P(=O)2NR b R c , C(=O)OR e , C(=O)R a , C(=O)NR b R c ,OC(=O)R a ,OC(=O)NR b R c , N.R. b C(=O)OR e , N.R. d C(=O)NR b R c , N.R. d S(=O)2NR b R c , N.R. d P(=O)NR b R c , N.R. b C(=O)R a or NR b P(=O)2R e and R5 is alkyl or substituted alkyl, heterocycle or substituted heterocycle, aryl or substituted aryl, amino or substituted amino; R6 and R9 are each independently hydrogen, halogen, cyano, nitro, CF3, OCF3, alkyl or substituted alkyl, heterocycle or substituted heterocycle, aryl or substituted aryl, or OR. a and R 14 and R 15 are independently hydrogen, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, heterocycle or substituted heterocycle, or aryl or substituted aryl, or optionally, 14 and R 15 together with the N to which they are attached form a heterocyclic ring or a substituted heterocyclic ring, R a is hydrogen, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, or aryl or substituted aryl; R b , R c and R d are independently hydrogen, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, heterocycle or substituted heterocycle, or aryl or substituted aryl, or optionally, b and R c together with the N to which they are attached form a heterocyclic ring or a substituted heterocyclic ring, R e is alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, or aryl or substituted aryl, And (b) a pharma- ceutically acceptable excipient, carrier, or diluent; The method of claim 1, further comprising administering (Item 6) A method for treating a condition selected from the group consisting of obesity, overweight, type II diabetes and metabolic syndrome in a mammal, including a human, comprising administering to a mammalian subject in need thereof: (a) A compound of formula V: [ka] or an enantiomer, diastereomer, tautomer, or a pharma- ceutically acceptable salt, solvate, ester, or prodrug thereof, which is effective in treating or preventing a condition selected from the group consisting of obesity, overweight, type II diabetes, and metabolic syndrome in a mammal, including a human, comprising a compound of formula V, or an enantiomer, diastereomer, tautomer, or a pharma- ceutically acceptable salt, solvate, ester, or prodrug thereof, wherein the symbols have the following meanings, independently selected for each occurrence: R1 is hydrogen, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, aryl or substituted aryl, OR a , S.R. a , S(=O)2R e , S(=O)2OR e , C(=O)OR d , C(=O)R a or C(=O)NR b R c and R3 and R 10 are each independently hydrogen, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, heterocycle or substituted heterocycle, aryl or substituted aryl; R4, R7, and R8 are each independently hydrogen, halogen, cyano, nitro, CF3, OCF3, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, aryl or substituted aryl, OR a , S.R. a , S(=O)R e , S(=O)2R e , P(=O)2R e , S(=O)2OR e , P(=O)2OR e , N.R. b R c , N.R. b S(=O)2R e , N.R. b P(=O)2R e , S(=O)2NR b R c , P(=O)2NR b R c , C(=O)OR e , C(=O)R a , C(=O)NR b R c ,OC(=O)R a ,OC(=O)NR b R c , N.R. b C(=O)OR e , N.R. d C(=O)NR b R c , N.R. d S(=O)2NR b R c , N.R. d P(=O)NR b R c , N.R. b C(=O)R a or NR b P(=O)2R e and R5 is a substituted alkyl, a heterocycle or a substituted heterocycle, an aryl or a substituted aryl; R6 and R9 are each independently hydrogen, halogen, cyano, nitro, CF3, OCF3, alkyl or substituted alkyl, heterocycle or substituted heterocycle, aryl or substituted aryl, or OR. a and R 11 is hydrogen or C 1~4 is alkyl, R 12 and R 13 are independently hydrogen, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, heterocycle or substituted heterocycle, or aryl or substituted aryl, or optionally, 12 and R 13 together with the N to which they are attached form a heterocyclic ring or a substituted heterocyclic ring, n is an integer selected from 2, 3, 4, 5, and 6; R a is hydrogen, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, or aryl or substituted aryl; R b , R c and R d are independently hydrogen, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, heterocycle or substituted heterocycle, or aryl or substituted aryl, or optionally, b and R c together with the N to which they are attached form a heterocyclic ring or a substituted heterocyclic ring, R e is alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, or aryl or substituted aryl, And (b) a pharma- ceutically acceptable excipient, carrier, or diluent; The method of claim 1, further comprising administering (Item 7) A method for treating a condition selected from the group consisting of obesity, overweight, type II diabetes and metabolic syndrome in a mammal, including a human, comprising administering to a mammalian subject in need thereof: (a) A compound of formula VI: [ka] or an enantiomer, diastereomer, tautomer, or a pharma- ceutically acceptable salt, solvate, ester, or prodrug thereof, which is effective in treating or preventing a condition selected from the group consisting of obesity, overweight, type II diabetes, and metabolic syndrome in a mammal, including a human, comprising a compound of formula VI or an enantiomer, diastereomer, tautomer, or a pharma- ceutically acceptable salt, solvate, ester, or prodrug thereof, wherein the symbols have the following meanings, independently selected for each occurrence: R1 is hydrogen, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, aryl or substituted aryl, OR a , S.R. a , S(=O)2R e , S(=O)2OR e , C(=O)OR d , C(=O)R a or C(=O)NR b R c and R2 is a monocyclic or bicyclic heterocycle or substituted heterocycle, aryl or substituted aryl; R3 is hydrogen, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, heterocycle or substituted heterocycle, aryl or substituted aryl, halogen, -OR a, -C(O)R a , -C(O)OR a , -NR a R b or S(O)NR a R b and R4, R5, R6 and R7 are each independently hydrogen, halogen, cyano, nitro, trihalomethyl, OCF3, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, aryl or substituted aryl, OR a , S.R. a , S(=O)R e , S(=O)2R e , P(=O)2R e , S(=O)2OR e , P(=O)2OR e , N.R. b R c , N.R. b S(=O)2R e , N.R. b P(=O)2R e , S(=O)2NR b R c , P(=O)2NR b R c , C(=O)OR e , C(=O)R a , C(=O)NR b R c ,OC(=O)R a ,OC(=O)NR b R c , N.R. b C(=O)OR e , N.R. d C(=O)NR b R c , N.R. d S(=O)2NR b R c , N.R. d P(=O)NR b R c , N.R. b C(=O)R a or NR b P(=O)2R eand T is O, S or R a and U, V and W are each independently carbon, N, O or S; X, Y, Z and A are each independently carbon or N, with the proviso that the ring in which X, Y, Z and A occur is aromatic; however, one of R4, R5, R6 and R7 is a substituted heterocycle or a substituted aryl; When X, Y, Z or A is each a heteroatom, then R4, R5, R6 or R7 is absent; Where: The substituted heterocycle and substituted aryl in R4, R5, R6 and R7 are the following groups: [ka] where: Q-2 is a heterocycle, C(=O)NR b R c or aryl, R n’ , R n’’ and R n’’’ are each independently hydrogen, halogen, cyano, nitro, trihalomethyl, OCF3, alkyl or substituted alkyl, OR a , S.R. a , C(=O)R a , C(=O)OR a , NH2, S(O)2NH2, NR b R c , heterocycle or substituted heterocycle, or aryl or substituted aryl; R a is hydrogen, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, or aryl or substituted aryl; R b , R c and R dare independently hydrogen, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, heterocycle or substituted heterocycle, or aryl or substituted aryl, or optionally, b and R c together with the N to which they are attached form a heterocyclic ring or a substituted heterocyclic ring, R e is hydrogen, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, or aryl. or substituted aryl; and (b) a pharma- ceutically acceptable excipient, carrier, or diluent; The method of claim 1, further comprising administering (Item 8) A method for treating a condition selected from the group consisting of obesity, overweight, type II diabetes and metabolic syndrome in a mammal, including a human, comprising administering to a mammalian subject in need thereof: (a) A compound of formula VII: [ka] or an enantiomer, diastereomer, tautomer, or a pharma- ceutically acceptable salt, solvate, ester, or prodrug thereof, which is effective in the treatment or prevention of a condition selected from the group consisting of obesity, overweight, type II diabetes, and metabolic syndrome in a mammal, including a human, comprising a compound of formula VII, or an enantiomer, diastereomer, tautomer, or a pharma- ceutically acceptable salt, solvate, ester, or prodrug thereof, wherein the symbols have the following meanings, independently selected for each occurrence: R1 is hydrogen, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, aryl or substituted aryl, OR a , S.R. a , S(=O)2R e , S(=O)2OR e , C(=O)OR d , C(=O)R a or C(=O)NR b R c and R3 is hydrogen, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, heterocycle or substituted heterocycle, aryl or substituted aryl, halogen, -OR a , -C(O)R a , -C(O)OR a , -NR a R b or S(O)NR a R b and R4, R6 and R7 are each independently hydrogen, halogen, cyano, nitro, trihalomethyl, OCF3, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, aryl or substituted aryl, OR a , S.R. a , S(=O)R e , S(=O)2R e , P(=O)2R e , S(=O)2OR e , P(=O)2OR e , N.R. b R c , N.R. b S(=O)2R e , N.R. b P(=O)2R e , S(=O)2NR b R c , P(=O)2NR b R c , C(=O)OR e, C(=O)R a , C(=O)NR b R c ,OC(=O)R a ,OC(=O)NR b R c , N.R. b C(=O)OR e , N.R. d C(=O)NR b R c , N.R. d S(=O)2NR b R c , N.R. d P(=O)NR b R c , N.R. b C(=O)R a or NR b P(=O)2R e and X, Z and A are each independently carbon or N, with the proviso that the ring in which X, Z and A occur is aromatic; Q-1 and Q-2 are independently a heterocycle, C(=O)NR b R c or aryl, R 2’ , R 2’’ , R 2’’’ and R 2’’’’ are each independently the absence, water nitrogen, halogen, cyano, nitro, trihalomethyl, OCF3, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, heterocycle or substituted heterocycle, aryl or substituted aryl, or OR a , N.R. b R c , N.R. b S(=O)2R e , N.R. b P(=O)2R e , S(=O)2NR b R c , P(=O)2NR b R c , C(=O)OR e , C(=O)R a , C(=O)NR b R c ,OC(=O)Ra ,OC(=O)NR b R c , N.R. b C(=O)OR e , N.R. d C(=O)NR b R c , N.R. d S(=O)2NR b R c , N.R. d P(=O)NR b R c , N.R. b C(=O)R a Or NR b P(=O)2R e and R 5’ , R 5’’ and R 5’’’ are each independently hydrogen, halogen, cyano, nitro, CF3, OCF3, alkyl or substituted alkyl, OR a , SRa, C(=O)R a , C(=O)OR a , NH2, S(O)2NH2, NR b R c , heterocycle or substituted heterocycle, or aryl or substituted aryl; Where: R a is hydrogen, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, or aryl or substituted aryl; R b , R c and R d are independently hydrogen, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, heterocycle or substituted heterocycle, or aryl or substituted aryl, or optionally, b and R c together with the N to which they are attached form a heterocyclic ring or a substituted heterocyclic ring, R eis hydrogen, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, or aryl or substituted aryl; and (b) a pharma- ceutically acceptable excipient, carrier, or diluent; The method of claim 1, further comprising administering (Item 9) A method for treating a condition selected from the group consisting of obesity, overweight, type II diabetes and metabolic syndrome in a mammal, including a human, comprising administering to a mammalian subject in need thereof: (a) A compound of formula VIII: [ka] or an enantiomer, diastereomer, tautomer, or a pharma- ceutically acceptable salt, solvate, ester, or prodrug thereof, which is effective in the treatment or prevention of a condition selected from the group consisting of obesity, overweight, type II diabetes, and metabolic syndrome in a mammal, including a human, comprising a compound of formula VIII, or an enantiomer, diastereomer, tautomer, or a pharma- ceutically acceptable salt, solvate, ester, or prodrug thereof, wherein the symbols have the following meanings, independently selected for each occurrence: R1 is hydrogen, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, aryl or substituted aryl, OR a , S.R. a , S(=O)2R e , S(=O)2OR e , C(=O)OR d , C(=O)R a or C(=O)NR b R c and R3 is hydrogen, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, heterocycle or substituted heterocycle, aryl or substituted aryl, halogen, -OR a , -C(O)R a , -C(O)OR a , -NR a R b or S(O)NR a R b and R4, R5 and R7 are each independently hydrogen, halogen, cyano, nitro, trihalomethyl, OCF3, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, aryl or substituted aryl, OR a , S.R. a , S(=O)R e , S(=O)2R e , P(=O)2R e , S(=O)2OR e , P(=O)2OR e , N.R. b R c , N.R. b S(=O)2R e , N.R. b P(=O)2R e , S(=O)2NR b R c , P(=O)2NR b R c , C(=O)OR e , C(=O)R a , C(=O)NR b R c ,OC(=O)R a ,OC(=O)NR b R c , N.R. b C(=O)OR e , N.R. d C(=O)NR b R c , N.R. d S(=O)2NR b R c , N.R. d P(=O)NRb R c , N.R. b C(=O)R a or NR b P(=O)2R e and X, Y and A are each independently carbon or N, with the proviso that the ring in which X, Y and A occur is aromatic; Q-1 and Q-2 each independently represent a heterocycle, C(=O)NR b R c or aryl, R 2’ , R 2’’ , R 2’’’ and R 2’’’’ are each independently absent, hydrogen, halogen, cyano, nitro, trihalomethyl, OCF3, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, heterocycle or substituted heterocycle, aryl or substituted aryl, or OR a , N.R. b R c , N.R. b S(=O)2R e , N.R. b P(=O)2R e , S(=O)2NR b R c , P(=O)2NR b R c , C(=O)OR e , C(=O)R a , C(=O)NR b R c ,OC(=O)R a ,OC(=O)NR b R c , N.R. b C(=O)OR e , N.R. d C(=O)NR b R c , N.R. d S(=O)2NR b R c , N.R. d P(=O)NR b R c , N.R. b C(=O)R a Or NR bP(=O)2R e and R 6’ , R 6’’ and R 6’’’ are each independently hydrogen, halogen, cyano, nitro, trihalomethyl, OCF3, alkyl or substituted alkyl, OR a , S.R. a , C(=O)R a , C(=O)OR a , NH2, S(O)2NH2, a heterocycle or a substituted heterocycle, or an aryl or a substituted aryl; Where: R a is hydrogen, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, or aryl or substituted aryl; R b , R c and R d are independently hydrogen, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, heterocycle or substituted heterocycle, or aryl or substituted aryl, or optionally, b and R c together with the N to which they are attached form a heterocyclic ring or a substituted heterocyclic ring, R e is hydrogen, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, or aryl or substituted aryl; and (b) a pharma- ceutically acceptable excipient, carrier, or diluent; The method of claim 1, further comprising administering (Item 10) A method for treating a condition selected from the group consisting of obesity, overweight, type II diabetes and metabolic syndrome in a mammal, including a human, comprising administering to a mammalian subject in need thereof: (a) A compound of formula IX: [ka] or an enantiomer, diastereomer, tautomer, or a pharma- ceutically acceptable salt, solvate, ester, or prodrug thereof, which is effective in the treatment or prevention of a condition selected from the group consisting of obesity, overweight, type II diabetes, and metabolic syndrome in a mammal, including a human, comprising a compound of formula IX, or an enantiomer, diastereomer, tautomer, or a pharma- ceutically acceptable salt, solvate, ester, or prodrug thereof, wherein the symbols have the following meanings, independently selected for each occurrence: R1 is hydrogen, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, aryl or substituted aryl, OR a , S.R. a , S(=O)2R e , S(=O)2OR e , C(=O)OR d , C(=O)R a or C(=O)NR b R c and R3 is hydrogen, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, heterocycle or substituted heterocycle, aryl or substituted aryl, halogen, -OR a , -C(O)R a , -C(O)OR a , -NR a R b or S(O)NR a R b and R4, R5 and R6 are each independently hydrogen, halogen, cyano, nitro, trihalomethyl, OCF3, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, aryl or substituted aryl, OR a , S.R. a , S(=O)R e , S(=O)2R e , P(=O)2R e , S(=O)2OR e , P(=O)2OR e , N.R. b R c , N.R. b S(=O)2R e , N.R. b P(=O)2R e , S(=O)2NR b R c , P(=O)2NR b R c , C(=O)OR e , C(=O)R a , C(=O)NR b R c ,OC(=O)R a ,OC(=O)NR b R c , N.R. b C(=O)OR e , N.R. d C(=O)NR b R c , N.R. d S(=O)2NR b R c , N.R. d P(=O)NR b R c , N.R. b C(=O)R a or NR b P(=O)2R e and X, Y and Z are each independently carbon or N, with the proviso that the ring in which X, Y and Z occur is aromatic; Q-1 and Q-2 each independently represent a heterocycle, C(=O)NR b Rc Or ants It is a rule, R 2’ , R 2’’ , R 2’’’ and R 2’’’’ are each independently absent, hydrogen, halogen, cyano, nitro, trihalomethyl, OCF3, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, heterocycle or substituted heterocycle, aryl or substituted aryl, or OR a , N.R. b R c , N.R. b S(=O)2R e , N.R. b P(=O)2R e , S(=O)2NR b R c , P(=O)2NR b R c , C(=O)OR e , C(=O)R a , C(=O)NR b R c ,OC(=O)R a ,OC(=O)NR b R c , N.R. b C(=O)OR e , N.R. d C(=O)NR b R c , N.R. d S(=O)2NR b R c , N.R. d P(=O)NR b R c , N.R. b C(=O)R a Or NR b P(=O)2R e and R 7’ , R 7’’ and R 7’’’ are each independently hydrogen, halogen, cyano, nitro, trihalomethyl, OCF3, alkyl or substituted alkyl, OR a , S.R. a , C(=O)R a , C(=O)OR a, NH2, S(O)2NH2, a heterocycle or a substituted heterocycle, or an aryl or a substituted aryl; Where: R a is hydrogen, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, or aryl or substituted aryl; R b , R c and R d are independently hydrogen, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, heterocycle or substituted heterocycle, or aryl or substituted aryl, or optionally, b and R c together with the N to which they are attached form a heterocyclic ring or a substituted heterocyclic ring, R e is hydrogen, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, or aryl or substituted aryl; and (b) a pharma- ceutically acceptable excipient, carrier, or diluent; The method of claim 1, further comprising administering (Item 11) A method for treating a condition selected from the group consisting of obesity, overweight, type II diabetes and metabolic syndrome in a mammal, including a human, comprising administering to a mammalian subject in need thereof: (a) a compound of formula X: [ka] or an enantiomer, diastereomer, tautomer, or pharma-ceutically acceptable salt, solvate, ester, or prodrug thereof, which is effective in the treatment or prevention of a condition selected from the group consisting of obesity, overweight, type II diabetes, and metabolic syndrome in a mammal, including a human; 1. A pharmaceutical composition comprising a diastereomer, tautomer, or pharma- ceutically acceptable salt, solvate, ester, or prodrug thereof, in a therapeutically effective amount, wherein the symbols have the following meanings, independently selected for each occurrence: R1 is hydrogen, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, aryl or substituted aryl, OR a , S.R. a , S(=O)2R e , S(=O)2OR e , C(=O)OR d , C(=O)R a or C(=O)NR b R c and R3 is hydrogen, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, heterocycle or substituted heterocycle, aryl or substituted aryl, halogen, -OR a , -C(O)R a , -C(O)OR a , -NR a R b or S(O)NR a R b and R5, R6, and R7 are each independently hydrogen, halogen, cyano, nitro, trihalomethyl, OCF3, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, aryl or substituted aryl, OR a , S.R. a, S(=O)R e , S(=O)2R e , P(=O)2R e , S(=O)2OR e , P(=O)2OR e , N.R. b R c , N.R. b S(=O)2R e , N.R. b P(=O)2R e , S(=O)2NR b R c , P(=O)2NR b R c , C(=O)OR e , C(=O)R a , C(=O)NR b R c ,OC(=O)R a ,OC(=O)NR b R c , N.R. b C(=O)OR e , N.R. d C(=O)NR b R c , N.R. d S(=O)2NR b R c , N.R. d P(=O)NR b R c , N.R. b C(=O)R a or NR b P(=O)2R e and Y, Z and A are each independently carbon or N, with the proviso that the ring in which Y, Z and A occur is aromatic; Q-1 and Q-2 each independently represent a heterocycle, C(=O)NR b R c or aryl, R 2’ , R 2’’ , R 2’’’ and R 2’’’’are each independently absent, hydrogen, halogen, cyano, nitro, trihalomethyl, OCF3, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, heterocycle or substituted heterocycle, aryl or substituted aryl, or OR a , N.R. b R c , N.R. b S(=O)2R e , N.R. b P(=O)2R e , S(=O)2NR b R c , P(=O)2NR b R c , C(=O)OR e , C(=O)R a , C(=O)NR b R c ,OC(=O)R a ,OC(=O)NR b R c , N.R. b C(=O)OR e , N.R. d C(=O)NR b R c , N.R. d S(=O)2NR b R c , N.R. d P(=O)NR b R c , N.R. b C(=O)R a Or NR b P(=O)2R e and R 4’ , R 4’’ and R 4’’’ are each independently hydrogen, halogen, cyano, nitro, trihalomethyl, OCF3, alkyl or substituted alkyl, OR a , S.R. a , C(=O)R a , C(=O)OR a , NH2, S(O)2NH2, a heterocycle or a substituted heterocycle, or an aryl or a substituted aryl; Where: R ais hydrogen, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocycle or substituted heterocycle, or aryl or substituted aryl; R b , R c and R d are independently hydrogen, alkyl or substituted alkyl, cycloalkyl or substituted cycloalkyl, heterocycle or substituted heterocycle, or aryl or substituted aryl, or optionally, b and R c together with the N to which they are attached form a heterocyclic ring or a substituted heterocyclic ring, R e is hydrogen, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, cycloalkyl or cycloalkyl; a) an alkyl group selected from the group consisting of aryl, aryl, aryl and aryl; and (b) a pharma- ceutically acceptable excipient, carrier or diluent. The method of claim 1, further comprising administering (Item 12) 12. The method according to any one of items 1 to 11, further comprising administering an additional agent selected from the group consisting of an insulin sensitizer, a diabetes agent, a metabolic syndrome agent, and a weight loss agent. (Item 13) 1. A method for reducing or ameliorating morbidity or mortality known to be associated with obesity, overweight, type II diabetes and metabolic syndrome in a mammal, including a human, said method comprising administering to a mammalian subject in need thereof: (a) The following [ka] [ka] and [ka] and a therapeutically effective amount of a pharmaceutical composition selected from the group consisting of an enantiomer, diastereomer, tautomer, or a pharma- ceutically acceptable salt, solvate, ester, or prodrug thereof; and (b) a pharma- ceutically acceptable excipient, carrier, or diluent; administering Morbidity or mortality known to be associated with obesity, overweight, type II diabetes, and metabolic syndrome are associated with excess weight, excess adiposity, BMI ≥ 25 kg / m 2 , insulin resistance, frequent urination, increased thirst, increased hunger, elevated blood pressure, elevated fasting plasma glucose, high serum triglycerides, low high density lipoprotein (HDL) levels, and elevated waist circumference. (Item 14) The morbidity or mortality rate is greater than or equal to BMI ≥ 30 kg / m 2 Item 14. The method according to item 13, wherein (Item 15) below: [ka] [ka] and pharma- ceutically acceptable salts thereof. (Item 16) 16. The compound according to item 15, wherein at least one of the hydrogens is deuterium.

Claims

[Claim 1] The invention described in the specification.

Citation Information

Patent Citations

  • Compositions of kinase inhibitors and their use for the treatment of cancer and other kinase-related diseases

    JP2010538091A

  • Use of egfr inhibitors to prevent or treat obesity

    US20090202529A1